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ABSTRACT 
Organic micropollutants (MPs) occur ubiquitously in the aquatic environment at trace 
concentrations, which presents great challenges for environmental monitoring. Solid-phase 
extraction (SPE) is a widely-used sample preparation procedure that concentrates MPs in 
environmentally derived water samples. SPE relies on columns packed with an adsorbent material 
that captures MPs from water samples. Loaded SPE adsorbents can then be eluted with organic 
solvents to release the captured MPs. The conventional adsorbent used for SPE is a hydrophilic-
lipophilic balanced material available from a variety of commercial vendors, often referred to as 
HLB. These HLB adsorbents feature stability at extreme pHs and high retention of polar and apolar 
organic MPs. The primary disadvantage of HLB adsorbent materials is price, which often makes 
sample preparation the most expensive step in an environmental monitoring workflow. In this 
research, novel porous β-cyclodextrin polymers (P-CDP) were evaluated as an alternative SPE 
adsorbent. Cyclodextrins are sustainably produced macrocycles of glucose, featuring a 
hydrophobic interior cavity that forms host-guest complexes with thousands of organic molecules. 
P-CDP is a polymer of cyclodextrin and is synthesized in one-step, making it relatively 
inexpensive to produce. The objective of this research was to develop an SPE procedure using P-
CDP and compare its performance to a conventional SPE procedure using HLB. A set of 189 MPs 
were included in the study and the P-CDP method was optimized to maximize efficiency in MP 
capture and MP release. The optimized P-CDP method exhibits moderate absolute recovery 
(≥60%) for 135 (75%) MPs and high absolute recovery (≥80%) for 121 (67%) MPs. The 
conventional HLB method exhibits moderate absolute recovery for 130 (72%) MPs and high 
absolute recovery for 109 (61%) MPs. The results of this research demonstrate that P-CDP could 
be used as a cost-effective SPE adsorbent.
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CHAPTER 1: INTRODUCTION  
1.1 Micropollutants (MPs) 
Good water quality is an important precondition for human health. With the increasing 
consumption of chemical products, waters are increasingly contaminated with organic substances 
and their residues, such as pharmaceuticals, personal care products (PCPs), household chemicals, 
and pesticides (Margot et al., 2015).  
These so-called organic micropollutants (MPs), or “trace contaminants”, have become a 
major environmental issue for wastewater treatment facilities and water utilities. With a broad 
range of sources, MPs enter water bodies through different flow paths, including transport from 
agricultural land, runoff from contaminated surface and ground waters, discharge from sewage 
systems (sewer overflow or leaking sewers), and untreated wastewaters (Eggen et al., 2014; 
Musolff et al., 2010). Although most of these MPs are measured at trace concentrations, ranging 
from ng L-1 to µg L-1, many MPs may still cause adverse environmental effects. For example, some 
industrial chemicals (bis (2-ethylhexyl) phthalate) and hormones (estrone) are confirmed 
endocrine disrupters (Ahel et al., 1994; Schwarzenbach et al., 2006). Some antibiotics which have 
been widely used in personal hygiene products for several decades, such as triclosan, are suspected 
to have the potential of enhancing bacterial resistance. In fact, triclosan was regarded as a safe 
antibacterial agent previously (Bedoux et al., 2012; McMurry et al., 1998), but in 2016 the U.S. 
Food and Drug Administration (FDA) issued a final rule and banned its usage in many personal 
care products (U.S. FDA, 2016). The U.S. Environmental Protection Agency (EPA) is also 
currently reviewing the risk of triclosan exposure to humans (Beyond Pesticides, 2016). Besides, 
some other emerging contaminants appearing in water resources have increasing environmental 
concerns. One group of closely watched emerging contaminants are the perfluoroalkyl substances 
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(PFASs), which have potential negative impacts for human health. Perfluorooctanoic acid (PFOA) 
and perfluorooctanesulfonic acid (PFOS) are the two most intensely used PFAS chemicals during 
many industrial processes. Studies conducted by the U.S. EPA showed that PFOA and PFOS could 
cause reproductive and immunological problems on lab animals, indicating its potential of having 
negative impacts on the immune system of humans, as well as the potential of contributing to 
cancer and thyroid disruption. Therefore, the U.S. EPA recently issued a human health advisory 
level for PFOA and PFOS at a combined concentration of 70 ng L-1 in drinking water (US EPA; 
Water Research Foundation, 2016). The level is quite low and could hardly be detected by current 
instruments directly without some sample concentration steps. 
Emerging concern over MPs occurring in water resources has motivated a number of 
monitoring studies focused on characterizing MP occurrence in groundwater, surface water, 
wastewater, and drinking water (Benner et al., 2013; Gilliom, 2007; Kolpin and Meyer, 2002; 
Pochodylo and Helbling, 2016). However, there are unique challenges associated with 
environmental monitoring for MPs. In the following sections, I will describe some of the important 
considerations for sample preparation and sample analysis with respect to MP monitoring.   
1.2 Sample Preparation 
Some of the biggest challenges for environmental monitoring of MPs are their occurrence 
at low concentrations, their occurrence in complex matrices, the large diversity of chemical 
structures, and the variability in mobilization from different sources. Therefore, careful sample 
collection and sample preparation techniques are required to enable robust analysis and detection. 
The conventional sample preparation workflow for MP analysis includes sample collection, 
sample handling (filtration, acidification, or basification) and sample clean-up (extraction, elution, 
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evaporation and reconstitution if necessary) (Comerton et al., 2009). Each of these steps will be 
discussed in the following. 
Sample collection. Representative samples are important for obtaining reliable data for decision 
making. Large sampling errors and sampling biases may contribute to the improper interpretation 
of collected data, and further lead to wrong conclusions. Appropriate sampling mode, sampling 
frequency, sample distributions, and sample numbers all help reduce errors and biases. First, the 
variations of flow determine the sampling mode. If the variations have a fixed pattern, some 
sampling time points with proper frequency could be selected; while if the variations have some 
rapid changes or are totally random, continuous sampling is a more suitable sampling mode (Ort, 
C., Lawrence, M. G., Rieckermann, J., and Joss, 2010). Second, the concentration variations of 
target MPs is the determining factor for choosing the sampling frequency. The frequency of 
changes of the concentrations must be carefully investigated beforehand, with the help of some 
online automatic instruments. The sampling intervals for collecting a 24-hour average sample 
largely depends on the frequency of changes of concentrations of the target MPs. Since many MPs 
exist in waters at very low concentrations and could not be detected directly by online instruments, 
a high frequency of sampling is usually adopted to ensure the representativeness of samples (Ort, 
C., Lawrence, M. G., Rieckermann, J., and Joss, 2010). Besides, the distribution of sampling 
locations is selected according to the field situation and MPs of interest, usually three replicates 
are needed to ensure the precision of collected data. The total number of samples are calculated 
based on the total area or the total load required for monitoring. Water samples are usually 
collected using trace clean preservative bottles. Some acids, bases, or other preservatives are often 
necessary for stabilizing different kinds of target compounds or preventing bacterial activity. 
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Samples are usually stored under 4 ℃ before handling for no longer than 48 hours (U.S. EPA, 
2005).  
Sample handling. Environmental samples usually first need filtration to remove large particles or 
interferences like natural organic matter (NOM), otherwise clogging could happen during the 
following clean-up steps or the analysis procedures. Cellulose and glass fiber filters are typically 
used to minimize adsorption of organic MPs (Comerton et al., 2009). Besides, the pH of the water 
sample is one of the key factors that may have impacts on analysis. pH can determine the speciation 
of target analytes and change the ionic strength of water samples, which may lead to different 
interactions with analytes and sorbents in the following clean-up steps. For example, some acidic 
drugs favor low pH (around 2.5) to achieve undissociated forms and high recoveries during 
extraction (Hartig et al., 1999). In addition, for complicated environmental samples such as lake 
waters or wastewaters, some field “spike” samples are used to measure the loss or gain of analytes 
due to degradation and water-matrix characteristics. These “spike” samples are achieved by adding 
labelled standards at certain predetermined concentrations into samples collected in field. The 
“spike” samples help determine the bias and reflect the actual concentration of analytes expressed 
as the ratio of the amount spiked (Myers, 2006). After handling, some clean-up steps are conducted 
before analysis, so that the instrumental analysis of target analytes could be more sensitive and 
precise. 
Sample clean-up. Sample clean-up usually refers to extraction and concentration. This step is the 
most important part of the overall sample preparation workflow. During clean-up processes, 
analytes will be extracted from water samples, the complexity of the matrix will be reduced, and 
the consequent analytical interferences will be minimized.  
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Generally speaking, classical liquid-liquid extraction (LLE) and solid-phase extraction 
(SPE) are the two major methods for sample extraction and concentration. LLE uses the 
differences of relative solubility of target analytes in two solvents as a means to separate analytes. 
Enrichment happens when solutes transfer from one solvent to another. Analytes in the feed 
solution (solvent containing analytes of interest) will gradually partition into another solvent. 
Many optimized LLE methods were widely used in clinical analysis, food analysis, and 
pharmaceutical bioseparation for decades (Silvestre et al., 2009; Xu et al., 2001). However, LLE 
is difficult to automate and cannot achieve high recoveries for polar compounds (Cabaleiro et al., 
2013; Silvestre et al., 2009), therefore it is seldom used for environmental water sample enrichment.  
Conventional SPE uses specific or mixed solid adsorbents to retain analytes from liquid 
samples; target analytes can be concentrated after desorbing from solid adsorbents into a small 
amount of solvent. SPE has many advantages over LLE for analyzing MPs in water samples. For 
example, target compounds adsorbed onto solid adsorbents can be stored for some period of time 
under proper conditions of handling and storage, with concentration or components unchanged. 
Further, reproducibility is largely improved with the stable solid adsorbents relative to LLE (Green 
and Pape, 1987). Besides, SPE generally requires a smaller volume of organic solvent than LLE, 
and is easier to automate for high sample throughput, therefore is more energy-saving and cost-
effective (Ahadi and Partoazar, 2011). Another important feature of SPE is that it can extract a 
wide range of organic analytes from complex matrices with portable configurations (Andrade-
Eiroa et al., 2016a). SPE has also made remarkable progress in terms of solvents,  and therefore 
has advantages specifically for the retention of polar drugs and metabolites compare to LLE (Ahadi 
and Partoazar, 2011; Cabaleiro et al., 2013; Saar et al., 2009; Titato and Lanças, 2005), which is 
very desirable for environmental monitoring and analysis for emerging contaminants. Recently, 
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SPE has been accepted in many EPA methods for analysis of organic pollutants in waters. For 
example, Method 1964 suggested conducting SPE with HLB cartridges to analyze personal care 
products (PCPs) and pharmaceuticals in waters (EPA, 2007).  
Choice of SPE adsorbents is the key point for the overall SPE procedure because different 
adsorbents have various selectivity, affinity and capacity (Pavlović et al., 2007). Conventional SPE 
adsorbents include chemically bonded silica with C18, ion-exchange materials, polymeric 
materials, and molecularly-imprinted polymers (MIPs). Many of those adsorbents are relatively 
limited to some certain kinds of target analytes (Gros et al., 2006a; Pavlović et al., 2007; Pichon, 
2000). Currently, hydrophilic-lipophilic balanced adsorption materials (HLB) remain the most 
popular SPE adsorbents for a wide range of organic compounds because it is pH stable and exhibits 
high capacity and good recoveries for many organic chemicals. Many multi-residue analytical 
methods aiming to quantify the occurrence of hundreds of MPs have been developed with HLB 
used for sample extraction and concentration (Cazorla-Reyes et al., 2011; Gros et al., 2006a, 2006b; 
Huntscha et al., 2012; Robles-Molina et al., 2014; Subedi et al., 2014; Zhang and Zhou, 2007). 
Although HLB has many advantages as an SPE adsorbent, the major disadvantage is the high unit 
price, which makes sample preparation one of the most expensive parts of the overall analytical 
workflow.  
1.3 Sample Analysis 
During the sample preparation step, target analytes are concentrated to detectable ranges 
and subsequently can be measured on a variety of analytical instruments directly. Two common 
analytical techniques are gas chromatography mass spectrometry (GC-MS) and liquid 
chromatography mass spectrometry (LC-MS). These analytical procedures include two parts. The 
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first step is the separation of target analytes, which is achieved by chromatography. With mass 
spectrometry, analytes can be detected and quantified. 
1.3.1 Gas Chromatography Mass Spectrometry (GC-MS) 
GC-MS is an analytical technique used for decades and has been most typically applied for 
analyzing volatile or non-polar compounds. The stationary phase of GC is a layer of inert fluid and 
the mobile phase is an inert gas, usually helium or nitrogen. During the operation, concentrated 
samples are injected into the instrument, and the carrier gas (mobile phase) carries samples to the 
analytical column, a division tube. Different analytes would be separated in the column based on 
different physiochemical properties and relating interactions (Pravallika, 2016). GC-MS is still 
being adopted in environmental laboratories as a reliable analytical technique. However, polar 
analytes with GC sometimes need to be converted to less polar analogues to achieve higher thermal 
stability and volatility (Radjenović et al., 2007). Therefore, GC is not a suitable analytical 
technique for analyzing MPs in waters, especially for more polar compounds such as acidic 
pharmaceuticals and pesticides.  
1.3.2 Liquid Chromatography Mass Spectrometry (LC-MS) 
LC-MS is the most popular analytical technique for analyzing environmental water 
samples for MPs. LC-MS usually applies to non-volatile, polar compounds such as the more polar 
pharmaceuticals and pesticides (Gómez et al., 2006; Gros et al., 2006b; Sargent et al., 2013). LC-
MS also employs a mobile phase, in this case an organic solvent, and a stationary phase, an 
analytical column packed with a solid material. Separation of analytes occurs on the analytical 
column as mobile phase passes through the column. In reversed-phase chromatography, polar 
compounds elute at short retention times and under highly aqueous mobile phase and apolar 
compounds elute at longer retention times and under highly organic mobile phase. LC-MS is more 
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favorable for organic micropollutants in the explicit identification of the analytes. Even with the 
same molecular mass, LC-MS can still separate and identify the unique peak of several analytes 
based on different product ions as well as molecular fragments (Comerton et al., 2009). The major 
drawback of LC-MS is the matrix effect of water samples, but with internal standards, matrix 
effects could be minimized. In this research, LC-MS was used as the final sample analysis method 
for detecting and quantifying a variety of MPs, covering a broad range of polarity. 
1.4 Research Objective 
Among the overall environmental monitoring workflow, sample preparation is the most 
expensive part, but it is also essential for generating reliable results. As mentioned in the preceding 
section, currently HLB is the universal SPE adsorbent used for analyte extraction and 
concentration with high unit price. Cheaper but also broadly effective adsorbents would be very 
desirable, and can provide significant value for MP monitoring.  
In this research, a novel porous β-cyclodextrin polymer (P-CDP) was adopted as the 
alternative SPE adsorbent. The unit price of  P-CDP is estimated to be one thousand times cheaper 
than HLB (Alsbaiee et al., 2016), and has been regarded as an effective adsorbent for the removal 
of a wide range of MPs in water (Ling et al., 2017). It was also demonstrated that P-CDP has the 
potential of releasing certain MPs with easy rinsing steps (Alsbaiee et al., 2016). Therefore, the 
objective of this research was to develop and evaluate a solid-phase extraction method for a wide 
range of micropollutants with P-CDP as the adsorbent. I hypothesized that P-CDP will outperform 
leading SPE materials (HLB) for the enrichment of micropollutants in aqueous samples. To test 
this hypothesis, (1) a conventional SPE method was adapted from the literature and the procedure 
was replicated using an HLB material and a mixture of 189 micropollutants, (2) the performance 
of the P-CDP material was compared to the HLB material using the previously described 
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conventional SPE method, and (3) the SPE method was systematically optimized to improve the 
performance of P-CDP as an SPE material. The result of this work is an optimized SPE method 
that uses P-CDP and outperforms conventional SPE methods that utilize HLB materials. 
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CHAPTER 2: EVALUATING A SOLID-PHASE EXTRACTION METHOD 
WITH NOVEL POROUS CYCLODEXTRIN POLYMERS 
Abstract 
Organic micropollutants (MPs) occur ubiquitously in the aquatic environment at trace 
concentrations, which presents great challenges for environmental monitoring. Solid-phase 
extraction (SPE) is a sample preparation procedure used for bringing concentrations of MPs to 
detectable levels. The conventional adsorbent used for SPE is a hydrophilic-lipophilic balanced 
material, often referred to as HLB. However, its high unit price makes sample preparation one 
of the most expensive parts of the overall environmental monitoring workflow. In this research, 
a novel β-cyclodextrin polymer (P-CDP) was studied as a potential SPE adsorbent and its 
performance was compared to HLB. Absolute recovery rates for 189 target MPs were first 
evaluated for P-CDP and HLB using conventional SPE conditions previously optimized for 
HLB (180 mg adsorbent, loading at pH 6, 5 mL methanol elution). Under these conditions, P-
CDP performed rather poorly as an SPE material. The SPE conditions were then systematically 
optimized to improve the absolute recovery rate of MPs on P-CDP. These optimization steps 
included evaluation of adsorbent mass, sample loading pH, and volume and composition of 
elution solvent. After optimization (500 mg adsorbent, loading at pH 3, 15 mL salt-assisted 
methanol elution), the P-CDP method exhibited moderate absolute recovery ((≥60%) for 135 
(75%) MPs and high absolute recovery (≥80%) for 121 (67%) MPs. The conventional HLB 
method exhibited moderate absolute recovery for 130 (72%) MPs and high absolute recovery 
for 109 (61%) MPs. The results of this research demonstrate that P-CDP could be used as a 
cost-effective SPE adsorbent.   
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2.1 Introduction 
During the last few decades, there has been increasing concerns over the occurrence of 
organic micropollutants (MPs) in the aquatic environment (Eggen et al., 2014; Geissen et al., 
2015; Petrie et al., 2014; Sorensen et al., 2015). MPs consist of a broad range of both 
anthropogenic compounds and natural substances including pharmaceuticals, personal care 
products, industrial chemicals, and pesticides (Luo et al., 2014). Sources of MPs are diverse 
and include industrial wastewater, domestic wastewater, landfill leachates, and runoff from 
agriculture or urban landscapes (Barbosa et al., 2016). Conventional WWTP processes are not 
specifically designed for eliminating MPs, and the majority of MPs will appear in vital aquatic 
environments such as surface water, ground water, or even in drinking water (Mompelat et al., 
2009; Ternes et al., 2015; Tijani et al., 2013). Although these MPs exist in waters at trace 
concentrations, mainly observed from several ng L-1 to a few µg L-1 (Petrie et al., 2014), their 
presence may cause negative ecological impacts to aquatic ecosystems (Carbajo et al., 2014; 
Eggen et al., 2014; Etchepare and van der Hoek, 2015; Haddad et al., 2015; Tijani et al., 2013).  
The very low concentrations of MPs and the broad range of sources complicate 
environmental monitoring. Although analytical instrumentation has developed rapidly, many 
MPs still cannot be detected at environmentally relevant concentrations using instruments 
directly such as with liquid-chromatography coupled to a mass spectrometer (LC-MS). In 
addition, environmental waters are complex and usually contain a lot of natural and 
anthropogenic chemical constituents. Sample preparation works are necessary for extracting, 
isolating and concentrating target analytes with certain characteristics from complex matrices 
(Kataoka, 2003). Sample pretreatment steps are of importance, and the quality of sample 
pretreatment is the key factor for determining the success of analysis. With proper sample 
enrichment methods, potential interferes in complex matrices could be removed so that 
reproducible analytical methods could be set up and target analytes could be enriched and 
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stabilized to provide more sensitive and precise analysis. Besides, tailored preparation works 
help increase the potential for automated monitoring (Pavlović et al., 2007). 
Recently, some sample enrichment methods have been developed to bring the 
concentration of MPs into detectable ranges and to extract target compounds from various 
matrices. Solid-phase extraction (SPE) is one of the most useful methods for effectively 
extracting organic compounds. It largely replaced the older techniques, such as liquid-liquid 
extraction (LLE), and has been widely used in biological analysis, environmental sample 
enrichment, and clinical treatments (Andersson, 2000; Andrade-Eiroa et al., 2016b; Cai et al., 
2003; Gómez et al., 2006; Lindsey et al., 2001). SPE uses solid adsorbents to extract target 
compounds from water samples, and is mostly used to prepare liquid samples and extracts of 
non-volatile or semi-volatile analytes (Pavlović et al., 2007).  It also has great tolerance for 
extracting polar compounds, and therefore fits the extraction of emerging contaminants well. 
One universal adsorbent for general use in SPE is HLB. HLB stands for hydrophilic-
lipophilic balance, the polymeric adsorbent has a poly (divinylbenzene-co-N-vinylpyrrolidone) 
skeleton with a nominal pore size of 8 nm and a specific surface area of about 800 m2 g-1 (Dias 
and Poole, 2002). Within the structure, the imbedded hydrophilic groups (pyrrolidone) provide 
good wettability and enhance retention for some polar compounds, while lipophilic groups 
promote interactions with more hydrophobic organic compounds (Fanali et al., 2017). HLB 
has very high capacity because of its high specific surface area and usually requires low elution 
volumes due to the small bed mass used in SPE cartridges. It is also pH stable and compatible 
with a broad range of organic solvents. Compared to some regular silica-based adsorbents, 
HLB has larger enrichment factors and permits more selective elution (Robles-Molina et al., 
2014). Its chemical structure and a picture of the solid form is shown in Figure 1. Many adapted 
HLB-based SPE procedures have been applied for the analysis of pesticides, metabolites, 
pharmaceuticals, and other emerging pollutants in waters (Heavner et al., 2005; Liu et al., 2006; 
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Zhang and Zhou, 2007). However, the unit price of HLB ranges from $13 to $31 per gram 
(Sigma-Aldrich, 2017; Waters, 2017), which also makes current sample preparation works one 
of the most expensive parts of the overall environmental monitoring workflow. Therefore, 
cheaper but also broadly effective SPE adsorbents are desirable.  
Last year, our research group reported the discovery of a novel porous β-cyclodextrin 
polymer (P-CDP), an inexpensive, sustainably produced macrocycle of glucose (Alsbaiee et 
al., 2016). β-cyclodextrin polymers form host-guest complexes with thousands of organic 
compounds, and have already been applied in biological and environmental related applications 
(Gidwani and Vyas, 2014; Jambhekar and Breen, 2016; Morin-Crini and Crini, 2013; Raoov 
et al., 2014). The basic shape of the cyclodextrin monomer is like a cup, which consists of a 
hydrophobic cavity and hydrophilic exterior. Similar to HLB, the hydrophobic cavity of P-
CDP could provide interactions with organic compounds, and the hydroxyl groups make P-
CDP contact thoroughly with water. Networked with proper cross-linkers, P-CDP remains 
stable in water. The chemical structure and the photo of its solid form is shown in Figure 2.  
The newly made P-CDP material has high water uptake rate due to its porous surface, 
and has outperformed conventional adsorbents like activated carbon in both batch and flow-
through experiments, suggesting great ability of extracting a broad range of MPs in waters 
(Ling et al., 2017). In addition, adsorbed bisphenol A could be released by simply rinsing the 
 
Figure 1. Oasis HLB in its chemical form (left) and in its solid form (right). 
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polymer with methanol at room temperature, indicating P-CDP has the potential for facile 
recovery of polar compounds (Alsbaiee et al., 2016). Therefore, P-CDP has great potential to 
capture and release MPs at environmentally relevant concentrations. The unit price of P-CDP 
is around $11 per kilogram based on pilot scale, which is more than one thousand times cheaper 
than HLB (Alsbaiee et al., 2016). I expect that P-CDP could be a useful or alternative SPE 
adsorbent. Therefore, the objective of this research was to develop and evaluate a solid-phase 
extraction method for a wide range of micropollutants with P-CDP as the adsorbent. I 
hypothesized that P-CDP will outperform leading SPE materials (HLB) for the enrichment of 
micropollutants in aqueous samples. To test this hypothesis, (1) a conventional SPE method 
was adapted from the literature and the procedure was replicated using an HLB material and a 
mixture of 189 micropollutants, (2) the performance of the P-CDP material was compared to 
the HLB material using the previously described conventional SPE method, and (3) the SPE 
method was systematically optimized to improve the performance of P-CDP as an SPE material. 
The result of this work is an optimized SPE method that uses P-CDP and outperforms 
conventional SPE methods that utilize HLB materials. 
 
Figure 2. P-CDP in its chemical form (left) and solid form (right). 
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2.2 Materials and Methods 
2.2.1 Standards and Reagents 
A total of 242 compounds were selected for the evaluation and optimization of a 
conventional solid-phase extraction procedure. These compounds are representative of seven 
groups of chemicals based on usage including pharmaceuticals (47%), pesticides (36%), 
industrial chemicals (7%), lifestyle chemicals (3%), hormones (3%), natural chemicals (3%), 
and illicit drugs (1%). These compounds were also selected based on their varied 
physicochemical properties including their size (McGowan volume), their pKa (and resulting 
charge state at pH 3 and pH 6), and their hydrophobicity (logKow and logD). A summary of all 
242 compounds including name, CAS number, supplier, chemical formula, usage category, 
and physicochemical properties is provided in Table A1 in Appendix A. Stock solutions of 
each compound and 44 isotope-labelled internal standards (ILIS) were prepared in appropriate 
solvents at a concentration of 1 g L-1 or 0.1 mg L-1 (depending on the solubility characteristics 
of the compound). An experimental mixture containing all 242 compounds was prepared in 
Milli-Q water at a concentration of 5 mg L-1 and a mixture of the ILISs was prepared in Milli-
Q water at a concentration of 10 mg L-1. All stock solutions and the experimental mixture were 
stored in a freezer at -20 ℃ until usage. Information on the solvents used for preparing the 
stock solutions is provided in Table A2 in Appendix A and information on the ILISs is provided 
in Table A3 in Appendix A. 
2.2.2 Solid-Phase Extraction 
The general solid-phase extraction (SPE) procedure was adapted from a previously 
reported study (Vogler, 2013). Synthetic water samples consisting of Milli-Q water spiked with 
the experimental mixture of compounds were used to validate the procedure using a 
conventional hydrophilic-lipophilic balance (HLB) SPE material (Oasis, Waters) and to 
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optimize the procedure for a novel porous cyclodextrin polymer (P-CDP) material synthesized 
as previously described (Alsbaiee et al., 2016). 
Sample preparation. Five 1 L water samples were prepared for each SPE test and labelled as 
the blank sample, the calibration sample, and three recovery samples (R1 – R3). A volume of 
100 µL of the 5 mg L-1 experimental mixture was spiked into each of the three recovery samples 
to yield a concentration of 500 ng L-1 of each of the 242 compounds. The five prepared samples 
were then filtered through glass microfiber filters (GF/F Circles, 47 mm, WhatmanTM; Nalgene 
filter) under vacuum to remove unwanted particles; recovery samples were filtered after the 
blank and calibration samples. Then, 1 mL of 1 M ammonium acetate buffer was added to each 
sample and the pH was adjusted to around 6 using 20% formic acid and a 1.4 N ammonia 
solution. 
Solid phase extraction. For each SPE test, five solid-phase extraction cartridges (PP, 6 mL, 
Supelco) were filled with a fixed mass (180 mg in the base case, higher masses during the 
optimization steps) of SPE material (either HLB or P-CDP) sandwiched between two porous 
frits (PE, 20 µm, Supelco). The SPE procedure was performed on a 12 port SPE vacuum 
manifold (Phenomenex). The cartridges were first conditioned with a mixture of 5 mL of pure 
methanol and 10 mL of Milli-Q water to remove residues and then loaded with the prepared 1 
L samples. The loading speed was controlled at 1~3 drops per second by adjusting the vacuum 
condition; the total loading period lasted from 5.5 hours to 7.5 hours. To evaluate compound 
capture, samples were taken from the effluent of the cartridges during the loading step and 
stored at 4 ℃ prior to analysis. After the loading step, all cartridges were dried under vacuum 
and were stored in a refrigerator overnight at 4 ℃. The next day, cartridges were removed from 
the refrigerator and warmed to ambient temperature (around 25 ℃) before elution. Elution was 
achieved by passing a fixed volume (5 mL in the base case, higher volumes during optimization) 
of organic solvent (methanol in the base case, other solvents or amendments during 
17 
optimization) over each cartridge and collecting the eluate in a centrifuge tube (15 mL, VWR). 
A volume of 100 µL of the 5 mg L-1 experimental mixture was spiked into the eluate from the 
calibration sample. A volume of 20 µL of the 10 mg L-1 ILIS mixture was spiked into the eluate 
of all five samples. Collected eluates were then evaporated under a gentle flow of high purity 
nitrogen gas until dry. The dried eluates were reconstituted in 100 µL of methanol and 900 µL 
of Milli-Q water and mixed with a vortex mixer (Fisher Scientific) for a few seconds. The 
reconstituted eluate was then transferred into a plastic syringe, filtered with 4 mm syringe 
filters (0.45 µm, VWR) into 2 mL amber vials, and stored in a freezer at -20℃ before analysis. 
2.2.3 Analytical Methods 
Quantification of analytes was by means of high-performance liquid chromatography 
(HPLC) coupled to a quadrupole-orbitrap mass spectrometer (MS) (QExactive, ThermoFisher 
Scientific). For concentrated samples (offline method), the analytical method was adapted from 
a previous study reporting the screening of transformation products of organic micropollutants 
by means of high-performance liquid chromatography (HPLC) coupled with high-resolution 
mass spectrometry (Helbling et al., 2010; Pochodylo and Helbling, 2016). Briefly, for the 
reconstituted SPE eluate, a volume of 30 µL of each sample was injected onto a 20 µL sample 
loop and separated on a reversed-phase analytical column (XBridgeTM C18 column; 3.5 µm; 
2.1 mm × 50 mm). The mobile phase consisted of HPLC grade water (A) and methanol (B) 
both acidified with 0.1 vol% formic acid and was delivered to the analytical column by a 
gradient pump at flowrate of 0.2 mL min-1. The mobile phase gradient started at 90% A and 
decreased linearly to 50% A over 4 mins and then to 5% A ever the next 13 minutes where the 
gradient was held constant for 8 minutes before switching back to 90% A to equilibrate the 
analytical column prior to injection of the next sample. The overall analysis for each sample 
lasted for 29 minutes. For the capture samples collected during SPE cartridge loading (online 
method), the analytical method was adapted from a previous study reporting the ultra-trace 
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level screening of polar and semi-polar organic chemicals (Huntscha et al., 2012; Ling et al., 
2017). Briefly, samples were injected at 5 mL volumes and were loaded onto an XBridge 
(Waters) C-18 Intelligent Speed (2.1 mm × 20 mm; particle size 5 µm) trap column with a 
loading pump delivering 98% A at 2 mL min-1. Elution from the trap column and onto the 
analytical column (XBridgeTM C18 column; 2.1 mm × 50 mm; particle size 3.5 µm) was 
performed using a gradient pump delivering 0.2 mL min-1 of mobile phase as described in the 
preceding. The HPLC-MS was operated with electrospray ionization (ESI) in positive and 
negative polarity modes. The MS acquired full-scan MS data within a mass-to-charge range of 
100-1,000 for each sample followed by a data-dependent acquisition of product ion spectra 
(MS/MS). Analytes from concentrated samples (offline method) were quantified based on the 
area ratio of the analyte to ILIS area response; analytes from capture samples (online method) 
were quantified based on the analyte response and external calibration standards. Limits of 
detection (LOD) for each analyte were determined as the lowest point of an external calibration 
curve in which at least 5 spectra could be observed at a certain intensity (greater than 105) with 
clear isotopic signatures and the most intense MS/MS fragments were still detected. All 242 
compounds were carefully examined, and 189 compounds with a LOD (offline method) less 
than 500 ng L-1 were selected as a final set of compounds for this study. Exact molecular masses, 
ionization behavior, retention times, the most intense MS/MS fragments, and limits of 
detection of each analyte are provided in Table B1 in Appendix B.  
2.2.4 Data Analysis 
To evaluate the performance of the two SPE materials (HLB and P-CDP), the absolute 
recovery rate, the capture recovery rate, and the relative recovery rate of each target compound 
was calculated. 
Absolute Recovery Rate. Absolute recovery rate (AbsRec) of each compound represents the 
overall SPE performance of the SPE materials. Because ILISs were spiked into the recovery 
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samples prior to evaporation and reconstitution, losses during these steps or due to matrix 
suppression are accounted for. The absolute recovery rate for each target compound is 
determined as the ratio of the recovered/actual concentration to the theoretical concentration, 
and was calculated as: 
AbsRec	 % = 	 ./01	21345	56	207580/9	:1;<=0 − ./01	21345	56	?=1@A	:1;<=0./01	21345	56	B1=4C/1345@	:1;<=0 − ./01	21345	56	?=1@A	:1;<=0 ×100%	 
Equation (1) 
In final optimized SPE recovery tests (salt-assisted elution SPE tests), we could only 
detect and report 180 out of 189 target compounds with low offline LODs (< 500 ng L-1) limited 
by current instrumental analytical method. 
Absolute Capture Rate. Absolute capture rate (AbsCap) of each compound is used to express 
the capture efficiency of the SPE materials during the loading step. For capture samples, no 
ILIS was added because the concentration of each compound was very low. The absolute 
capture rate for each target compound is determined as the ratio of the differences of the peak 
areas, and was calculated as: 
AbsCap	 % = (1 − ./01	56	K@6=L0@3	:1;<=0 − ./01	56	M66=L0@3	:1;<=0./01	56	K@6=L0@3	:1;<=0 − ./01	56	?=1@A	:1;<=0 )×100%		 
Equation (2) 
Because the online method used for measuring the absolute capture rate has a higher 
LOD than the offline method, we could only report absolute capture rates for 159 of the 189 
target compounds with online LODs of <100 ng L-1.  
Relative Recovery Rate. Relative recovery rate (R/C Ratio) of each compound is used to 
describe the recovery potential of each SPE material for each compound during the elution step. 
A higher R/C ratio means the compound can be more easily released from the SPE material by 
the eluent, and therefore can be more efficiently recovered. The R/C ratio considers only the 
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rate of release of the mass of each compound that was captured, allowing us to more carefully 
study the release of captured compounds. The R/C Ratio was calculated as: 
2 B Ratio	 % = .CR5=Lt0	207580/9	2130	 .CR207.CR5=L30	B1<3L/0	2130	 .CRB1< ×100%				 
Equation (3) 
Because the R/C ratio includes measurements made with both the online and offline 
methods which have different LODs, we could only report relative recovery rates for 159 of 
the 189 target compounds which have low offline (< 500 ng L-1) and online (< 100 ng L-1) 
LODs.  
All recovery data are reported as the average of triplicate or duplicate measurements 
and error bars represent the minimum and maximum measurement. All capture data are 
reported as the average of six or nine replicate measurements and error bars represent the 
standard deviations. 
2.3 Results and Discussion 
The evaluation of P-CDP as a potential SPE material included three parts. First, a 
conventional SPE method was adapted from the literature and the procedure was replicated 
using an HLB SPE material and a mixture of 242 micropollutants (only 189 of the MPs could 
be detected with our analytical method). The results of replicated experiment was compared 
with the literature reported results for the 115 overlapping compounds and confirmed good 
agreement. Second, the performance of the P-CDP material was compared to the HLB material 
using the previously described conventional SPE method. The results showed that the 
performance of the P-CDP as an SPE material was rather poor under the conditions of the 
conventional SPE method that had been developed and optimized for HLB materials. Third, 
the SPE method was systematically optimized to improve the performance of P-CDP as an SPE 
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material. The result of this work is an optimized SPE method that uses P-CDP and outperforms 
conventional SPE methods that utilize HLB materials.  
2.3.1 Adaption of conventional SPE method 
The conventional SPE method was adapted from a previously described study which 
presents the development of a multilayer SPE method for polar organic compounds (Vogler, 
2013). The author of this study also reports absolute recovery rates for 418 environmentally 
relevant compounds with a single layer SPE method using Oasis® HLB as the adsorbent. I first 
aimed to replicate this SPE procedure with the 242 compounds included in my test mixture. 
Some minor changes were made to the method, based on availability of SPE materials. Briefly, 
HLB was provided by a different producer and the mass used was 180 mg instead of the 200 
mg used in the previous study. Additionally, a one-step elution process with just 5 mL of 
methanol was employed instead of the three-step elution process described in the previous 
work. All other steps were controlled to be as described in the conventional SPE method 
including loading speed and pH adjustment to 6.3.  
Absolute recovery rates were 
calculated for the 189 compounds in my test 
mixture that could be detected using Equation 
(1). A comparison of the absolute recovery 
rates among 115 compounds that were 
included in the previous study and my study 
are presented in Figure 3. The error bars on the 
data collected in the present work reflect the 
minimum and maximum values of triplicate 
measurements. A total of 103 of the 
compounds (90%) had minimum or maximum 
 
Figure 3. Comparison of absolute recovery rates for 
115 compounds from a previously reported experiment 
and a new experiment with HLB as the SPE adsorbent. 
Error bars represent minimum and maximum of 
triplicate measurements. 
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values within 10% of the average value, reflecting the accuracy and precision of the triplicate 
measurements. The red line represents the situation in which the absolute recovery rate is the 
same when comparing the present work to the previous work and the dashed lines represent a 
20% deviation between the experiments. A total of 83 of the compounds (72%) had less than 
a 20% deviation between the experiments. Considering the differences in the producer of the 
HLB materials, the masses of HLB material used in each of the studies, and the simplified step 
used for elution, these results reflect similar performances of the HLB materials between the 
experiments and provide evidence that my SPE experiments could reproduce previously 
reported data. The absolute recovery rates for each of the 189 compounds and the 115 
overlapping compounds are provided in Table C1 in Appendix C.   
2.3.2 Comparison of P-CDP to HLB as SPE materials 
2.3.2.1 Modification of SPE cartridge packing procedure 
The SPE cartridge packaging 
procedure for HLB involves filling each 
cartridge with a fixed mass of HLB 
sandwiched between two porous frits with a 
pore size of 20 µm. However, the average 
particle size of P-CDP (~15 µm) is much 
smaller than OasisR  HLB (55 µm), and in 
preliminary experiments I observed that 
some P-CDP particles can leak into the 
eluent when SPE cartridges are packed with P-CDP in this way, introducing a light yellow 
color to the eluate. This is not an ideal situation, as leaking adsorbents can capture compounds 
in the eluent, leading to overestimation of capture potential and underestimation of recovery 
potential of P-CDP materials. Therefore, several options were explored for packing SPE 
 
Figure 4. Modified packaging method used in P-CDP 
SPE tests. 
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cartridges with P-CDP materials to eliminate material leaking. The final configuration utilizes 
0.2 grams of glass wool (8 µm porosity) (Yavuz et al., 2013) and two additional frits at the 
bottom of each cartridge, as shown in Figure 4. This configuration eliminated the yellow color 
observed in the eluents and was considered adequate for our P-CDP method.  
2.3.2.2 Evaluation of overall performance of P-CDP as an SPE material 
I next aimed to apply the previously 
described SPE procedure that was designed 
for HLB materials with P-CDP materials 
used as the adsorbents. The only change to 
the method was in the way the cartridges 
were packed, as described in the preceding 
section. The test mixture of 242 compounds 
was used and all other process variables 
were controlled. The only noticeable 
difference between the experiments was in 
the pressure required to maintain the 
desired flowrate through the SPE cartridges; the vacuum pump was pulling a vacuum of 13 
inches of mercury to maintain a 2-3 drop per minute flowrate through the P-CDP materials 
whereas only 4 inches of mercury were required to meet the same flowrate through HLB 
materials. The difference can be attributed to the new packing configuration, the smaller size 
of the P-CDP materials, and the broader particle size distribution of the P-CDP materials, which 
allows fine particles to fill void spaces. 
Absolute recovery rates for each of the 189 compounds that could be detected were 
calculated using Equation (1) and are compared to the absolute recovery rates measured using 
HLB materials in Figure 5. The error bars in Figure 5 reflect the minimum and maximum 
 
Figure 5. Comparison of absolute recovery rates of 189 
targeted compounds with P-CDP vs HLB as adsorbent; 
error bars represent the minimum and maximum of 
triplicate measurements. 
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values of triplicate measurements. The red line represents the situation in which the absolute 
recovery rate measured for HLB is the same as the absolute recovery rate measured for P-CDP, 
and data plotted above the red line would reflect a situation in which that compound exhibited 
greater recovery on P-CDP than HLB. Considering the previously reported observations of 
nearly instantaneous uptake of a diverse set of polar organic compounds on the P-CDP (Ling 
et al., 2017) and facile regeneration with methanol (Alsbaiee et al., 2016), the expectation for 
this comparison was that much of the data would fall along the red line or above the red line. 
However, only 27 of the compounds (14%) could be recovered better when P-CDP is used as 
the SPE material under these conditions. If 60% is selected as the criterion to describe a 
“moderate or good” absolute recovery rate (Cazorla-Reyes et al., 2011; Raoov et al., 2014; 
Vogler, 2013), then only 60 compounds (32%) could be recovered well using P-CDP as an 
adsorbent under these conditions, while 137 compounds (72%) could be recovered well with 
HLB. The absolute recovery rates for each of the 189 compounds on P-CDP under these 
conditions are provided in Table C1 in Appendix C.  
The absolute recovery rates of most compounds were relatively poor for P-CDP under 
the experimental conditions that have been optimized for HLB materials (Jeong et al., 2017; 
Mazzella et al., 2008; Robles-Molina et al., 2014; Tavengwa et al., 2016; Vogler, 2013). 
However, there are two parts to absolute recovery; there is compound capture by the SPE 
material and there is compound release from the SPE material. It is not clear if the poor 
performance of the P-CDP material was due to deficiencies in compound capture during 
loading or compound release during elution or both. In the following sections, experiments 
were designed for addressing the question of whether deficiencies in capture during loading or 
release during elution or both are contributing to the poor absolute recovery performance of P-
CDP. Capture ability is assessed by measuring the absolute capture rate as described in 
25 
Equation (2) and the release potential is assessed by calculating the relative recovery rate as 
described in Equation (3).  
2.3.2.2 Evaluation of capture ability of P-CDP vs HLB 
To measure the absolute capture rate, a series of experiments were conducted where 
effluent were collected from SPE cartridges during compound loading at three different time 
points (1 hour, 3 hour, and 5 hour). These experiments were conducted with SPE cartridges 
loaded with either HLB or P-CDP materials and in duplicates. Because the concentration of 
many compounds was very low after capture by the SPE materials, samples were measured by 
means of the online method described in the preceding, which had suitable LODs for 159 of 
the compounds in my test mixture.  
 Absolute capture rates for each 
compound were calculated for each SPE 
material using Equation (2) and are 
compared in Figure 6. The error bars in 
Figure 6 reflect the standard deviation of 
six measurements derived from the three 
samples collected from duplicate 
experiments. These data show that under 
the conditions optimized for HLB, 
absolute capture of the 159 compounds on 
P-CDP is relatively poor. I selected 80% 
as the criterion to describe “moderate or good” absolute capture rates. Only 86 compounds 
(54%) could be captured well using P-CDP as adsorbent under these conditions, while 146 
compounds (92%) could be captured well with HLB. The efficacy of HLB under these 
conditions was further evidenced by an accounting of compounds that were “perfectly captured” 
 
Figure 6. Comparison of absolute capture rates of the 
159 compounds with P-CDP and HLB as adsorbents; 
error bars represent the standard deviation of six 
measurements.  
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with absolute capture rates greater than 95%. Based on this criterion, only 69 compounds (43%) 
were perfectly captured by P-CDP whereas 104 compounds (65%) could be perfectly captured 
with HLB. The poor absolute capture performance of P-CDP could partly explain the poor 
absolute recovery performance, though a careful evaluation of compound release is also 
warranted. The absolute capture rates for each of the 159 compounds on HLB and P-CDP are 
provided in Table C2 in Appendix C.  
2.3.2.3 Evaluation of release potential of P-CDP vs HLB 
To measure the release potential, 
the data from the absolute recovery rate 
experiments and absolute capture rate 
experiments were used to calculate the 
relative recovery ratio (R/C ratio) as 
provided in Equation (3). The R/C ratio can 
be interpreted as the rate at which captured 
compounds are released during the elution 
step of the SPE method. Perfect elution of 
captured compounds would result in an R/C 
ratio of one; values less than one can be 
interpreted as a situation where some of the captured compound remains on the adsorbent 
following the elution step. Because data from the capture experiments are needed to calculate 
the R/C ratio, the R/C ratio for the 159 compounds detected in the capture study were calculated.  
The R/C ratios for each compound were calculated using Equation (3) and are 
compared for each SPE material in Figure 7. There are several notable observations in these 
data. First, the majority of the compounds exhibit R/C ratios near one for HLB. A total of 117 
compounds (74%) had an R/C ratio greater than 0.80 for HLB, reflecting the potential for 
 
Figure 7. Comparison of relative recovery rates (R/C 
ratio) of 159 target compounds with P-CDP and HLB 
as adsorbents; error bars represent the minimum and 
maximum of triplicate measurements. 
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compounds to be easily released from HLB with 5 mL of methanol. Second, relatively few 
compounds had an R/C ratio near one for P-CDP. Only 67 compounds (42%) had an R/C ratio 
greater than 0.80 for P-CDP, reflecting that the majority of the compounds that are captured by 
P-CDP are incompletely released with 5 mL of methanol. Finally, it is notable that many 
compounds have a R/C ratio of zero for P-CDP, indicating that they were captured but not 
released at all with 5 mL of methanol. The poor R/C ratios calculated for compounds on P-
CDP further suggest that release potential may also partly explain the poor absolute recovery 
performance. Careful steps to optimize capture and release will be required prior to using P-
CDP as an SPE material. The R/C ratios for each of the 159 compounds on HLB and P-CDP 
are provided in Table C2 in Appendix C.     
2.3.3 Optimization of P-CDP Based SPE Procedure 
I determined that the performance of P-CDP as an SPE material is relatively poor when 
compared to HLB, under experimental conditions that had been optimized for HLB. However, 
there are several notable properties of P-CDP that could be exploited to improve either the 
capture ability or the release potential of compounds on P-CDP. First, based on the 
thermodynamics of equilibrium of adsorbents, the uptake of target compounds should be 
increased when more adsorbents are added (Benjamin and Lawler, 2013). Therefore, increasing 
the mass of P-CDP materials in each cartridge may enhance the capture rates of target 
compounds. Second, P-CDP has many hydroxyl groups at the outside of its cyclodextrin 
monomers, as well as fluorine-containing cross-linkers; these functional groups might impart 
some charge selectivity to adsorbate uptake. Indeed, pH-dependent uptake was observed in 
removal of MPs in aqueous samples using P-CDP (Ling et al., 2017) and other fluorinated 
polymer networks (Byun et al., 2016). P-CDP adopted in this research showed positively 
charged favorable property during adsorption tests while no such charge favorable property 
has been observed for HLB (Jeong et al., 2017; Zhang and Zhou, 2007). Since pH will influence 
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the ionic forms of many target compounds, lowering the pH of water samples might turn neutral 
or negatively charged compounds to more positively charged state, which might help improve 
the capture performance of P-CDP materials. As for potential recovery ability, the type and 
volume of elution solvent are important factors that should be considered during elution 
(Andrade-Eiroa et al., 2016c; He and Blaney, 2015). Considering the pH-dependent 
observation of preferential uptake of positively charged molecules, the pH and ionic strength 
of the elution solvents may have impacts on the potential recovery ability of P-CDPs. 
2.3.3.1 Optimization of capture ability (Mass Study) 
One of the major advantages of P-CDP as an SPE adsorbent is their price relative to 
HLB. Rough estimates suggest that P-CDP could be produced at prices that are several orders 
of magnitude less than those for which HLB is currently commercially available (Alsbaiee et 
al., 2016; Waters, 2017). Therefore, increasing the mass of P-CDP used in each SPE cartridge 
could be explored as an economically viable means to improve the absolute capture rate.  
A series of experiments were conducted in which SPE cartridges were packed with 
increasing masses of P-CDP ranging between 180 mg and 1000 mg. Samples of the effluent 
were collected during the loading step to measure the absolute capture rate as described in the 
preceding. The resulting data were distributed into bins that represent different levels of 
absolute capture rates (AbsCap<20; 20%£AbsCap<40%; 20%£AbsCap<40%; 
40%£AbsCap<60%; 60%£AbsCap<80%; 80%£AbsCap<99%; AbsCap³99%) among the 
experiments. An accounting of the number of compounds that were assigned to each bin for 
each experiment is presented in Figure 8. The bars presented in Figure 8 represent the number 
of compounds assigned to each bin, and the lines in Figure 8 represent the cumulative number 
of compounds with absolute capture rates above 80% (green) and 95% (blue). The data for 
HLB are provided as a means for comparison. 
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There are clear performance gains as P-CDP mass is added to the SPE cartridges. From 
100 mg to 500 mg, there is a clear increase in the number of compounds with absolute capture 
rates greater than 99% and a concomitant decrease in the number of compounds with absolute 
capture rates less than 20%. This proves that added mass improves the capture ability of P-
CDP materials, likely for thermodynamic reasons as a new equilibrium situation is established 
(Huang et al., 2013; Liu et al., 2011). Interestingly, the performance gains diminish rather 
markedly between 500 mg and 1000 mg, where only incremental gains in performance are 
noted. This may be the result of having achieved an infinite dilution condition at 500 mg of P-
CDP, with added mass not changing the thermodynamics of the situation considerably 
(Jambhekar and Breen, 2016). Most notably, the absolute capture rate of P-CDP at 500 mg is 
superior to the performance of HLB at 180 mg. One would naturally expect that the 
perforamnce of HLB would also increase if the mass of HLB increased by a factor of almost 
 
Figure 8. Distribution of absolute capture rates for compounds with different mass of P-CDP as adsorbent. 
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three, though the cost of HLB precludes that as an option. Based on these results, I defined 500 
mg of P-CDP as the optimal mass for the P-CDP SPE method. 
With the new values of absolute 
capture rate estimated at a mass of 500 mg of 
P-CDP, a revised comparison of the absolute 
capture rates for each compound and for each 
SPE material is presented in Figure 9. The 
error bars reflect the standard deviation of six 
measurements derived from the three 
samples collected from duplicate 
experiments. These data show that the 
absolute capture rates of many of the 
compounds improved significantly with 
additional P-CDP mass. The number of compounds with a “moderate or good” absolute capture 
rate increased from 86 compounds (54%) to 130 compounds (82%), and the number of 
compounds that were “perfectly captured” increased from 69 compounds (43%) to 119 
compounds (75%). Nevertheless, there remain 19 compounds (12%) that have absolute capture 
rates of less than 40%, which indicates that further optimization of capture ability will be 
required. The absolute capture rates for each of the 159 compounds on 500 mg of P-CDP are 
provided in Table C3 in Appendix C.   
2.3.3.2 Optimization of capture ability (pH Study) 
I next aimed to examine the physicochemical properties of each of the compounds 
included in my test mixture to determine whether any compound property contributed to either 
excellent capture ability or poor capture ability. Particular attention was paid to the McGowan 
Volume (MV, molecular size) and charge state of the compound based on previous reports on 
 
Figure 9. Distribution of absolute capture rates of 159 
target compounds with P-CDP (500 mg per cartridge) 
and HLB as adsorbents; error bars represent standard 
deviations of six measurements.  
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the influence of these parameters on 
adsorption of polar organic compounds on 
cyclodextrin polymers (Crini, 2003; Hu et 
al., 2014; Huang et al., 2013; Ling et al., 
2017; Pan et al., 2010; Yang et al., 2015). 
The logD (charge-dependent lipophilicity) 
which is often used to describe the 
adsorption of organic compounds onto 
hydrophobic surfaces was also examined 
(Kadar et al., 2010; Kah and Brown, 2007). 
Based on an examination of these properties, 
I found that the charge state of the compound was an important determinant of compound 
capture ability on P-CDP. This agrees with the previously reported study that charge state plays 
an important role in the selectivity of MPs for P-CDP during adsorption (Ling et al., 2017). 
This observation is detailed in Figure 10, where the comparison of the absolute capture rates 
for each compound and for each SPE material as a function of charge state of the compound at 
pH 6 is presented. Interestingly, every compound that is positively charged at pH 6 is “perfectly 
captured” (AbsCap≥95%) by P-CDP. To the contrary, neutral compounds and compounds that 
are negatively charged are captured to varying extents. The majority of the compounds with 
the poorest absolute capture rates (AbsCap < 20%) were negatively charged compounds. Also 
important to note, no such charge exclusivity was observed for capture by HLB. Based on these 
observations, I hypothesized that lowering the pH of the water during the SPE loading step will 
improve compound capture due to the changing charge state of the compounds.  
A series of experiments were conducted in which the pH of the water samples used for 
compound loading were adjusted to between pH 3 and pH 7 using 10% formic acid or a 0.7 N 
 
Figure 10. Distribution of absolute capture rates of 159 
target compounds with P-CDP (500 mg per cartridge) 
and HLB as adsorbents; error bars represent standard 
deviations of six measurements; charge states are 
estimated at pH 6 from Marvin. 
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ammonia solution. A mass of 180 mg of P-CDP was used and samples of the effluent were 
collected during the loading step to measure the absolute capture rate. The resulting data were 
distributed into bins as described in the preceding and an accounting of the number of 
compounds that were assigned to each bin and for each experiment is presented in Figure 11. 
The bars presented in Figure 11 represent the number of compounds assigned to each bin, and 
the lines in Figure 11 represent the cumulative number of compounds with absolute capture 
rates above 80% (green) and 95% (blue).  
Whereas the distribution of the compounds among the removal groups was relatively 
stable in the range of pH 5 to pH 7, there is a clear performance gain at pH 3. This can be 
explained by the pKa values of the 159 compounds included in this analysis; the majority of 
the compounds have pKa values between 3 and 5, meaning that those compounds that become 
 
Figure 11. Distribution of absolute capture rates for target compounds with different loading pHs. 
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neutral or positively charged at lower values of pH will only respond to pH below 5. Because 
only a few compounds had a pKa below 3, I did not consider lower pHs in this study.  
Based on the optimization of P-CDP 
mass and the pH of the waters used for 
compound loading, an optimal method 
combining 500 mg of P-CDP and a loading 
condition of pH 3 was selected. An 
experiment to evaluate this optimized 
condition was performed and a comparison 
of the optimized absolute capture rates on P-
CDP to the absolute capture rates previously 
measured on HLB is presented in Figure 12. 
The error bars reflect the standard deviation 
of nine measurements derived from the three samples collected from triplicate experiments. 
These data show that the absolute capture rates of many of the compounds improved even more 
under the conditions of optimal mass and pH. The number of compounds with a “moderate or 
good” absolute capture rate increased to 147 compounds (92%), and the number of compounds 
that were “perfectly captured” increased to 141 compounds (89%). Only 5 compounds (3%) 
have absolute capture rates of less than 40%. These five compounds were metolachlor ESA, 
propachlor ESA, propachlor OXA, hexamethylphosphoramide, and sucralose. After examining 
the properties of these five compounds, I hypothesized that the charge state, the logD, and 
unique functional groups contributed to this result. First, compounds with a negative charge 
and high hydrophilicity are poorly captured by P-CDP. Metolachlor ESA and propachlor ESA 
are the only two compounds that are negatively charged at pH 3 and have negative values of 
logD. Propachlor OXA has a pKa close to 3, indicating that half of the compound is negatively 
 
Figure 12. Distribution of absolute capture rates for 
159 target compounds with P-CDP (500 mg per 
cartridge at pH 3) and HLB; error bars represents 
standard deviations of nine measurements. Charge 
states are estimated at pH 3 from Marvin.  
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charged at a pH of 3, and it also has a negative logD value. No other compounds included in 
this study have a similar combination of acidity and hydrophilicity. Second, some unique 
functional groups may explain the poor capture of hexamethylphosphoramide (HMPA) and 
sucralose. HMPA is a special compound with a phosphoric triamide structure. The P-O bond 
in its structure is highly polar with a significant partial negative charge residing on the oxygen 
atom. This unique functional group along with its small molecular volume (Ling et al., 2017) 
likely contributes to its poor capture ability. Sucralose is a neutral molecule at pH 3 and pH 6, 
but is very hydrophilic and has a negative logD value. Sucralose also is a cyclic aliphatic 
containing five hydroxyl groups, rendering it very polar. As such, sucralose is a poor adsorbate 
with P-CDP. The optimized absolute capture rates for each of the 159 compounds are provided 
in Table C3 in Appendix C.  
Finally, an absolute recovery test was performed based on the optimized capture 
procedure to determine whether there was 
any improvement relative to the base case 
presented in Figure 5. The absolute recovery 
rates for each compound were calculated and 
are compared with HLB in Figure 13. 
Whereas there was some clear improvement 
in the absolute recovery of some compounds 
compared to the base case, the absolute 
recovery of most compounds on P-CDP 
remained relatively poor; only 68 (36%) of 
the compounds could be recovered 
moderately (AbsRec ≥	60%) with P-CDP. This suggests that further optimization of the 
method will be required, with focus now on optimization of the release potential. The optimized 
Figure 13. Distribution of absolute recovery rates for 
189 target compounds with P-CDP (with optimized 
loading condition) and HLB as adsorbents; error bars 
represent the minimum and maximum of triplicate 
measurements. 
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absolute recovery rates for each of the 189 compounds that were detected are provided in Table 
C4 in Appendix C. 
2.3.3.3 Optimization of release potential (Volume Study) 
Capture ability could only partly explain the overall poor absolute recovery of 
adsorbates on P-CDP. Therefore, the optimization of the recovery step was performed by 
considering the type of elution solvent, the volume of the elution solvent, and chemical 
amendments to the elution solvent.  
Selection of a proper elution solvent is one of the most important parameters for 
adsorbate recovery in SPE. some preliminary recovery tests were conducted in advance using 
some conventional elution solvents including methanol, ethanol, acetone, acetonitrile, and 
ethyl acetate (Bhaskar et al., 2004; Huck and Bonn, 2000; Maldaner and Jardim, 2012; Moon 
et al., 2008; Yu et al., 2003). Interestingly, acetone, acetonitrile, and ethyl acetate could not 
pass through the P-CDP, apparently due to swelling of the material, since the thin top layer of 
polymers became darker after contacting those organic solvents. Both methanol and ethanol 
passed through the P-CDP adequately and both produced similar recovery results. Therefore, I 
decided to use methanol as the elution solvent for the P-CDP based SPE method.  
I next examined whether the volume of methanol was an important determinant of 
adsorbate recovery. The base case applied for the HLB materials used 5 mL of methanol, and 
here I also conducted recovery experiments using 10 mL and 15 mL of methanol. The resulting 
data were distributed into bins as described in the preceding and an accounting of the number 
of compounds that were assigned to each bin and for each experiment is presented in Figure 
14. The bars presented in Figure 14 represent the number of compounds assigned to each bin, 
and the green line is the cumulative number of compounds that have “moderate or good” 
absolute recovery rates. 
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 There are clear performance gains as the volume of methanol used for elution is 
increased from 5 mL to 15 mL, with an increase in the number of compounds with absolute 
recovery rates greater than 80% and a concomitant decrease in the number of compounds with 
absolute capture rates less than 20%. This proves that increasing the volume of methanol used 
for elution can improve absolute recovery rates. However, the total volume of methanol that 
could be used was limited due to the size of the centrifuge tubes available for eluate capture 
and the size of the SPE manifold. It is likely that further increases in eluent volume may lead 
to further gains in absolute recovery rates. Interestingly, the distribution of absolute recovery 
rates among the compounds when using 15 mL methanol as the eluent is rather extreme, with 
nearly half of the compounds recovered well and the other half of the compounds rather poorly 
recovered (AbsRec<20%). This suggests that the increase in volume of the eluent enhances the 
 
Figure 14. Distribution of absolute recovery rates for compounds using different volume of methanol as elution 
solvents. 
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removal of some types of compounds (likely those undergoing hydrophobic interactions) but 
has no effect on other types of compounds (likely those undergoing electrostatic interactions). 
Based on these results and practical considerations, I defined 15 mL of methanol as the optimal 
volume for the P-CDP SPE method. 
With the new values of absolute 
recovery rate estimated with 15 mL of 
methanol as the eluent, a revised comparison 
of the absolute recovery rates for each 
compound and for each SPE material is 
presented in Figure 15. The error bars reflect 
the standard deviation of six measurements 
derived from the minimum and maximum 
values of triplicate experiments. These data 
show that the absolute recovery rates of 
many of the compounds improved 
significantly with additional methanol volume. However, even with the increased volume of 
methanol, many compounds still are not recovered well from the P-CDP; only 96 (51%) of the 
compounds were recovered moderately (AbsRec≥60%) using P-CDP compared to 137 (72%) 
using HLB. Nevertheless, many of the target compounds had similar absolute recovery rates 
using P-CDP and HLB as adsorbents, whereas some compounds are still distributed along the 
x-axis in Figure 15, indicating no recovery at all. The absolute recovery rates of each of 189 
compounds using 15 mL of methanol as the eluent are provided in Table C4 in Appendix C. 
 
Figure 15. Distribution of absolute recovery rates of 
189 target compounds with P-CDP (15 mL methanol 
elution) and HLB; error bars represent the minimum 
and maximum of triplicate measurements.  
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2.3.3.4 Optimization of release potential (Salt Study) 
Analogous to my approach in 
evaluating capture performance, I next 
examined the physicochemical properties of 
each of the compounds included in my test 
mixture to determine whether any compound 
property contributed to either excellent 
recovery ability or poor recovery ability. the 
McGowan volume (MV), charge state of the 
compound, and the logD were considered 
again. Based on an examination of these 
properties, the charge state of the compound 
was also found to be the most important determinant of compound recovery potential. This 
observation is detailed in Figure 16, where the comparison of the absolute recoveries of each 
compound and for each SPE material as a function of charge state of the compound at pH 6 is 
presented. From Figure 16, it is clear that none of the positively charged compounds are 
recovered from P-CDP with methanol, while most negatively charged and neutral compounds 
have similar absolute recovery rates for both adsorbents. This result matches the speculation 
that P-CDP “likes” positively charged compounds, and the hypothesis derived from this result 
is that the positively charged compounds are attracted too tightly onto P-CDP to be released. 
The final optimization step is to identify a suitable procedure to release positively charged 
compounds from P-CDP. 
Two options were identified for enhancing the release of positively charged compounds 
from P-CDP. First, I hypothesized that increasing the pH of the eluent solvent would enhance 
the release of positively charged compounds by changing their charge state from positive to 
 
Figure 16. Distribution of absolute recovery rates for 
189 target compounds with P-CDP (15 mL methanol 
elution) and HLB as adsorbents; error bars represent 
the minimum and maximum of the triplicate 
measurements; charge states are estimated at pH 6 from 
Marvin. 
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neutral. The pH of the methanol eluent was increased to a pH of 10 by adding either ammonia 
or sodium hydroxide. Unfortunately, the pH modified methanol could not pass through the P-
CDP material, and the color of the top thin polymer layer changed, apparently due to swelling 
of the material. As a result, this hypothesis could not be directly tested. 
Second, I hypothesized that increasing the ionic strength of the eluent solvent would 
enhance the release of positively charged compounds by means of ion exchange. The ionic 
strength of the methanol eluent was increased by dissolving 100 mg of sodium chloride into 
15 mL of methanol at ambient temperature (around 25 ℃) to yield a 6.67 g L-1 solution. The 
amended eluent was passed through the loaded SPE cartridges under vacuum at 20 inches of 
mercury. High concentrations of sodium are known to interfere with electrospray ionization 
mass spectrometry (Sargent et al., 2013), 
but internal standards were used to correct 
for changes in ionization efficiency. During 
instrumental analysis procedure, 9 
compounds were missing due to the 
interference of sodium ions, therefore 
absolute recovery rates for only 180 
compounds were calculated and compared 
with HLB in Figure 17. These data reveal 
two important observations. First, the 
presence of sodium ions enables the release 
of positively charged compounds from P-CDP resulting in a greatly improved absolute 
recovery for those compounds. Second, the absolute recovery rates with my optimized SPE 
procedure compare favorably with the optimized SPE procedure for HLB; among all 180 
targeted compounds with robust data, 135 (75%) could be moderately recovered 
 
Figure 17. Distribution of absolute recovery rates for 
180 target compounds with P-CDP and HLB 
adsorbents under optimized condition; error bars 
represent the minimum and maximum of triplicate 
measurements; charge states are estimated at pH 6 from 
Marvin. 
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(AbsRec≥60%) with P-CDP versus 130 (72%) with HLB, and 121 (67%) could be well 
recovered (AbsRec≥80%) using P-CDP versus 109 (61%) with HLB.    
There are 17 compounds in the bottom right section of Figure 17, indicating these 
compounds could be recovered moderately or well with HLB as adsorbent but had poor 
recoveries with P-CDP. Among those 17 compounds, metolachlor ESA, 
hexamethylphosphoramide and sucralose are three compounds that confirmed previously 
cannot be captured well with P-CDP, so their absolute recoveries were poor as well. The 
remaining 14 compounds are listed in Table 1.  
Table 1. Fourteen Compounds that could be recovered well by HLB but not P-CDP. 
Compound Name 
Charge 
State 
(pH 6) 
LogD 
(pH6) MV 
HLB 
AbsRec (%) 
P-CDP 
AbsRec (%) 
P-CDP 
AbsCap (%) 
Candesartan - 2.49 3.16 120.0 20.6 100.0 
Trinexapac-ethyl - -1.67 1.84 122.3 17.5 99.2 
Amisulpride + -0.13 2.81 70.4 1.0 100.0 
Hydrocodone + -0.59 2.21 84.3 57.8 100.0 
2-ethyl-2-phenyl 
malonamide 
monohydrate 
n -2.92 1.65 69.1 14.4 NA 
Acetochlor n 3.50 2.14 129.0 29.5 100.0 
Alachlor n 3.50 2.14 129.0 29.5 100.0 
Dehydroacetic 
Acid n 0.42 1.19 125.6 26.9 100.0 
Molinate n 2.34 1.55 96.4 36.6 NA 
Sulfadimethoxine n 1.22 2.12 93.3 22.1 98.7 
Sulfamethazine n 0.61 2.00 128.0 21.3 100.0 
Sulfamethoxazole n 0.60 1.72 98.4 32.7 100.0 
Sulfathiazole n 0.93 1.69 94.0 1.1 NA 
Ranitidine HCl z -0.36 1.77 72.2 12.6 NA 
 
Reasons for the poor recoveries for these compounds vary and are not always clear. 
Since ion exchange principles were used to help during elution, charge state is not as important 
as described for capture part. There are no common features among molecular size or logD 
values, either. However, some special functional groups might play important roles here. 
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Among those 14 compounds, four are neutral sulfonamides (sulfamethoxine, sulfamethazine, 
sulfamethoxazole and sulfamethiazole). Neutral sulfonamides have been demonstrated in other 
studies to be recovered well with regular silica based material and ion exchange materials at 
neutral pH with pure methanol as an elution solvent (Lindsey et al., 2001), but cannot be 
recovered well in complex matrices due to matrix effects (Pavlović et al., 2007). While in this 
study, P-CDP could not recover neutral sulfonamides well. Nevertheless, the mechanisms 
contributing to the poor recoveries of those 14 compounds with P-CDP remain unknown. 
Further studies are required to more fully understand the factors that influence capture and 
release of organic chemicals on P-CDP. The final absolute recovery rates for each of the 180 
compounds based on the fully optimized SPE procedure are provided in Table C4 in Appendix 
C.   
2.3.4 Optimized P-CDP Based SPE Procedure 
After systematically improving the capture and recovery ability of P-CDP, an optimized 
SPE procedure was developed with P-CDP as the adsorbent. The optimized steps are 
determined as: (1) after filtration and before the loading step, the pH of the water samples are 
adjusted to 3.0±0.1 using 10% formic acid; (2) pack 500 mg P-CDP in each SPE cartridge, 
then load each 1 L water sample to corresponding cartridges; (3) during the elution step, 
dissolve 100 mg sodium chloride in 15 mL methanol to yield a 6.67 g L-1 methanol-salt mixture, 
then load the elution mixture through cartridge under vacuum. After P-CDP based SPE 
procedure, the concentration of target compounds would be enriched 1000 times. Among 189 
tested compounds, except for 9 compounds that cannot be detected as a result of interference 
by sodium ions during instrumental analysis, 67% of the total compounds have high absolute 
recovery rates (≥80%), which outperformed HLB material.
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CHAPTER 3: FUTURE WORK 
3.1 Conclusions 
During the research, an offline SPE method was developed and optimized with a novel P-
CDP material as the adsorbent. This novel material was reported to be a great adsorbent in batch 
experiments, and its unique charge selectivity property was proved by this research as well as 
previous studies (Ling et al., 2017). Realizing the fact that P-CDP favors positively charged 
compounds, I improved the capture rates of target compounds by increasing the mass of adsorbents 
and lowering the pH of water samples. Many neutral compounds, including ubiquitous water 
contaminants carbamazepine and DEET, were fully captured with increased mass even at neutral 
pH. Likewise, some compounds that are neutral or negatively charged at neutral pH become neutral 
or positively charged compounds at pH 3 and exhibited improved capture. For example, ibuprofen 
and warfarin exhibited greatly improved capture at pH 3. Recovery rates were also improved using 
ion exchange principles. With the help of 100 mg sodium chloride, 67% of target compounds can 
achieve a recovery rate above 80% with one step elution. 
After optimization, the P-CDP material could compete with the leading SPE material, HLB, 
in both capture and recovery steps, and could be used as an alternative and good SPE adsorbent 
for more than 120 of compounds examined. We estimate that P-CDP is one thousand times cheaper 
than HLB, but is also broadly effective and can be easily manipulated in SPE workflows. 
Additionally, P-CDP favors positively charged compounds during capture step, therefore it can 
also be used for charge selective treatments via simple pH controls, such as charge selective 
adsorption or MP removal and charge selective SPE. 
Above all, several conclusions can be drawn as: 
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(i)  An equivalent mass of HLB outperforms P-CDP as an SPE adsorbent when loaded at pH 
6 and eluted with 5 mL of methanol; 
(ii)  P-CDP material has great ability for capturing and releasing a broad range of MPs, and 
can perform better than HLB under optimized conditions; 
(iii) The optimized condition for P-CDP based SPE was 500 mg P-CDP, loading at pH 3, and 
elution with 15 mL methanol containing 100 mg sodium chloride;  
(iv) The charge state of compounds is the most important factor influencing both capture and 
release of adsorbates with P-CDP as adsorbent; 
(v)  Some special properties including compounds that are both highly acidic and hydrophilic 
and those containing neutral sulfonamide groups limit capture and release on P-CDP; 
(vi) P-CDP can be used as a charge selective adsorbent in both MP treatment and SPE 
procedures. 
3.2 Future Work 
In the future, the P-CDP based SPE procedure could be improved even further. First, the 
optimization of the elution step was not perfect. A very high concentration of sodium chloride was 
used in the elution step (almost half of the solubility of sodium chloride in methanol), and the high 
concentration of sodium ions leads to the interferences during instrumental analysis. An optimal 
concentration of sodium chloride should be selected following a systematic series of elution tests. 
Different concentrations of sodium chloride in methanol should be tested, and the lowest 
concentration with the highest recovery rates would be the optimal concentration.  
Furthermore, calcium chloride might be a preferred alternative salt that would also assist 
elution. Calcium is a divalent cation and calcium chloride can be dissolved easily in methanol, so 
the ionic strength of the elution solvent would also be increased with calcium chloride, and we 
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may need lower concentrations of calcium chloride to elute same moles of MPs. Besides, calcium 
ions would not interfere with instrumental analysis for there aren’t any calcium adducts formed 
with target compounds, and we could get better and more accurate measurements compared to 
sodium chloride elution. Similar to the experiments expected for sodium chloride, the 
concentration of calcium chloride would also need to be optimized if applicable.  
In addition to procedure optimizations, the optimized SPE method needs to be applied to 
real water samples, like tap water and lake water. In this research we already demonstrated the 
good performance of P-CDP in aqueous solution, and some batch experiments demonstrated that 
the adsorption ability of P-CDP will not be affected by NOM in real waters (Ling et al., 2017). I 
therefore expect good recoveries using P-CDP in SPE procedure with real water samples. To 
analyze MPs in real waters, the concentration of MPs might be a little bit lower, but the matrix is 
much more complex than the synthetic solution prepared in this research. To minimize the 
complexity of real waters, I would first select fifty stable MPs with low LODs and different 
polarizability as “standard MPs”, a mixture of those compounds would be prepared. After filtration 
and adding buffers, I would spike in the mixture of the “standards” at three different concentration 
levels, such as 10 ng L-1, 50 ng L-1 and 250 ng L-1. Internal standards could help diminish the 
matrix effects and recoveries could be calculated for those fifty MPs. In this way, the performance 
of P-CDP in real waters could be evaluated. From all capture and recovery data for a broader range 
of MPs, we would also figure out the possible adsorption and desorption mechanisms of P-CDP 
materials, and therefore further develop different SPE conditions for different SPE target. 
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APPENDICES 
Appendix A - Property Information of Compounds and Reagents 
Table A1. Physiochemical properties of all 242 compounds. 
No.a Compound Name CAS No. Supplier
b Chemical Formula pKa
c Log Kowd Charge 3e Charge 6e LogD 3e LogD 6e MVf Classg 
1 10,11-dihydrocarbamazepine 58955-93-4 Sigma C15H14N2O3 12.84 -0.21 n n 0.85 0.85 1.85 Pharm 
2 2-aminobenzimidazole 934-32-7 Sigma C7H7N3 8.11 0.88 + + -1.26 -1.23 1.01 Pesticide 
3 2-ethyl-2-phenyl malonamide monohydrate 7206-76-0 Fluka C11H14N2O2 15.73 0.40 n n -2.92 -2.92 1.65 Pharm 
4 2-mercaptobenzothiazole 149-30-4 Sigma C7H5NS2 3.63 1.83 n - 2.88 2.88 1.13 Pesticide 
5 2-methyl-4-isothiazolin- 3-one (MI) 2682-20-4 Fluka C4H5NOS NA -0.83 n n 0.23 0.23 0.80 Pesticide 
6 2,4-D 94-75-7 Fluka C8H6Cl2O3 2.81 2.62 - - 2.10 -0.52 1.38 Pesticide 
7 2,6-dichlorobenzamide 2008-58-4 Fluka C7H5Cl2NO -1.42 0.90 n n 1.44 2.31 1.22 Pesticide 
8 2,6-dimethoxyphenol 91-10-1 Aldrich C8H10O3 9.37 1.16 n n 1.35 1.35 1.17 Lifestyle 
9 6-benzylaminopurine 1214-39-7 Sigma C12H11N5 3.42 1.23 + n 1.48 1.50 1.67 Pesticide 
10 Abacavir 136470-78-5 Fluka C14H18N6O -0.27 1.62 + n -2.77 -2.07 2.09 Pharm 
11 Abscisic Acid 21293-29-8 Sigma C15H20O4 4.74 2.38 n - 2.09 0.81 2.13 Pesticide 
12 Acebutolol HCl 37517-30-9 Fluka C18H28N2O4 9.57 1.19 + + -0.98 -0.25 2.76 Pharm 
13 Acephate 30560-19-1 Sigma C4H10NO3PS 6.54 -0.90 n n 0.04 0.03 1.27 Pesticide 
14 Acesulfame K 55589-62-3 Sigma C4H4KNO4S 2.00 -1.33 - - -0.21 -1.97 0.98 Lifestyle 
15 Acetaminophen 103-90-2 USP C8H9NO2 9.46 0.27 n n 1.62 0.97 1.17 Pharm 
16 Acetamiprid 135410-20-7 Sigma C10H11ClN4 -0.27 2.55 + n -0.06 1.11 1.67 Pesticide 
17 Acetazolamide 1424-27-7 Sigma C4H5N4NaO3S2 6.55 -0.72 n n -0.42 -2.75 1.34 Pharm 
18 Acetochlor 34256-82-1 Fluka C14H20ClNO2 16.60 3.37 n n 3.50 3.50 2.14 Pesticide 
19 Adrenalone HCl 99-45-6 Sigma C9H11NO3 7.50 0.47 + + -2.80 -1.40 1.37 Pharm 
20 Adrenosterone 382-45-6 Aldrich C19H24O3 NA 1.41 n n 3.01 3.01 2.36 Hormone 
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21 Alachlor 15972-60-8 Fluka C14H20ClNO2 16.60 3.37 n n 3.59 3.59 2.14 Pesticide 
22 Albuterol Sulfate 18559-94-9 Fluka C13H21NO3 9.40 0.64 + + -2.36 -2.21 1.98 Pharm 
23 Amicinonide 51022-69-6 Sigma C28H35FO7 13.59 NA n n 3.20 3.20 3.62 Pharm 
24 Amisulpride 71675-85-9 Sigma C17H27N3O4S -0.11 1.11 + + -2.52 -0.13 2.81 Pharm 
25 Amitriptyline HCl 50-48-6 Fluka C20H23N 9.76 4.95 + + 1.31 1.50 2.40 Pharm 
26 Amphetamine 300-62-9 Cerilliant C9H13N 10.01 1.76 + + -1.23 -1.19 1.24 Pharm 
27 Ampicillin 69-53-4 Sigma C16H19N3O4S 3.24 1.45 + z -1.40 -3.49 2.48 Pharm 
28 Arecoline HBr 63-75-2 Sigma C8H13NO2 8.23 0.78 + + -2.84 -1.56 1.26 Natural 
29 Atenolol 29122-68-7 USP C14H22N2O3 9.67 -0.03 + + -4.64 -4.50 2.18 Pharm 
30 Atenolol Acid 56392-14-4 Aldrich C14H21NO4 3.54 -2.34 + z -1.69 -1.24 2.14 Pharm 
31 Atomoxetine HCl 83015-26-3 Sigma C17H21NO 9.80 4.23 + + 0.57 0.67 2.19 Pharm 
32 Atrazin-2-Hydroxy 2163-68-0 Fluka C8H15N5O 12.48 -1.74 n n -2.84 -2.84 1.56 Pesticide 
33 Atrazin-desethyl 6190-65-4 Sigma C6H10ClN5 3.38 1.78 + n -1.57 0.23 1.34 Pesticide 
34 Atrazine 1912-24-9 Fluka C8H14ClN5 3.20 2.82 + n -0.96 0.98 1.62 Pesticide 
35 Atrazine-desethyl- desisopropyl 3397-62-4 
Sigma 
Fluka C3H4ClN5 3.58 0.32 + n -2.58 -0.88 0.92 Pesticide 
36 Atropine 51-55-8 Sigma C17H23NO3 9.39 1.91 + + -1.93 -1.57 2.28 Pharm 
37 Azoxystrobin 131860-33-8 Fluka C22H17N3O5 0.94 1.58 n n 4.22 4.22 2.92 Pesticide 
38 Baclofen 1134-47-0 Cerilliant C10H12ClNO2 3.89 -1.32 + z -1.36 -0.78 1.58 Pharm 
39 Bendiocarb 22781-23-3 Sigma C11H13NO4 14.76 2.55 n n 2.12 -0.25 1.60 Pesticide 
40 Bentazon 25057-89-0 Fluka C10H12N2O3S 2.03 1.67 - - 0.06 -0.19 1.67 Pesticide 
41 Benzisothiazolin-3-on (BIT) 2634-33-5 Sigma C7H5NOS 9.50 0.64 n n 1.92 0.66 1.03 Pesticide 
42 Benzotriazole 95-14-7 Sigma C6H5N3 0.22 1.17 n n 1.30 1.30 0.86 Industrial 
43 Benzotriazole-methyl-1H 136-85-6 Fluka C7H7N3 0.45 1.71 n n 1.81 1.81 1.01 Industrial 
44 Benzoylecgonine 519-09-5 Cerilliant C16H19NO4 3.15 -1.32 + z -0.88 -0.59 2.16 Drug 
45 Bis(2-ehtylhexyl) phthalate 117-81-7 Fluka C24H38O4 NA NA n n 8.03 8.03 3.40 Industrial 
46 Bromacil 314-40-9 Fluka C9H13BrN2O2 9.95 1.68 n n 2.41 0.13 1.63 Pesticide 
47 Caffeine 58-08-2 USP C8H10N4O2 -1.16 0.16 n n -0.55 -0.55 1.36 Lifestyle 
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48 Candesartan 139481-59-7 TRC C24H20N6O3 -1.45 4.79 n - 5.18 2.49 3.16 Pharm 
49 Carbamazepine 298-46-4 Sigma Aldrich C15H12N2O 15.96 2.25 n n 2.59 2.81 1.81 Pharm 
50 Carbendazim 10605-21-7 Sigma C9H9N3O2 -1.81 1.55 + n 2.31 0.13 1.36 Pesticide 
51 Carbofuran 1563-66-2 Fluka C12H15NO3 14.76 2.30 n n 2.62 0.55 1.69 Pesticide 
52 Carisoprodol 78-44-4 Cerilliant C12H24N2O4 15.06 2.36 n n 0.55 -0.84 2.15 Pharm 
53 Celecoxib 169590-42-5 Fluka C17H14F3N3O2S -0.41 3.47 n n 4.01 4.01 2.47 Pharm 
54 Chloridazon 1698-60-8 Fluka C10H8ClN3O -1.77 0.76 n n 1.11 1.11 1.52 Pesticide 
55 Cimetidine 51481-61-9 Fluka C10H16N6S 4.51 0.57 + + -2.83 -0.83 1.96 Pharm 
56 Ciprofloxacin 85721-33-1 Sigma C17H18FN3O3 -0.22 0.00 + z -1.68 -0.95 2.30 Pharm 
57 cis-diltiazem 42399-41-7 Cerilliant C22H26N2O4S 8.18 2.79 + + -0.77 0.57 3.14 Pharm 
58 Citalopram HBr 59729-33-8 Cerilliant C20H21FN2O 9.78 3.74 + + 0.26 0.44 2.53 Pharm 
59 Clarithromycin 81103-11-9 Sigma C38H69NO13 8.38 5.24 + + -1.60 0.89 5.91 Pharm 
60 Climbazole 38083-17-9 Sigma C15H17ClN2O2 6.49 3.76 + + 3.75 3.98 2.19 Pharm 
61 Clofibric Acid 882-09-7 Fluka C10H11ClO3 3.37 2.84 n - 2.75 0.32 1.54 Pharm 
62 Codeine 76-57-3 Cerilliant C18H21NO3 9.19 1.28 + + -2.16 -1.68 2.21 Pharm 
63 Corticosterone 50-22-6 Sigma C21H30O4 -0.26 1.99 n n 2.02 2.02 2.74 Pharm 
64 Cotinine 486-56-6 Cerilliant C10H12N2O -1.83 0.34 + n -0.72 0.19 1.39 Drug 
65 Coumarin 91-64-5 Sigma C9H6O2 NA 1.51 n n 1.78 1.78 1.06 Natural 
66 Cyanazine 21725-46-2 Sigma C9H13ClN6 -0.63 2.51 n n -1.27 -0.33 1.77 Pesticide 
67 Cyflufenamid 180409-60-3 Sigma C20H17F5N2O2 15.15 5.60 n n NA NA 2.66 Pesticide 
68 DEET 134-62-3 
Sigma 
Aldrich 
Fluka 
C12H17NO -0.95 2.26 n n 2.50 2.50 1.68 Pesticide 
69 Dehydroacetic Acid 520-45-6 Sigma C8H8O4 6.49 0.78 n n 0.44 0.42 1.19 Pesticide 
70 Desvenlafaxine 93413-62-8 Fluka C16H25NO2 8.87 2.72 + + -0.91 -0.22 2.23 Pharm 
71 Dexamethasone 50-02-2 Sigma C22H29FO5 12.42 1.72 n n 1.68 1.68 2.91 Pharm 
72 Dextromethorphan HBr 125-71-3 Fluka C18H25NO 9.85 3.60 + + -0.01 0.15 2.24 Pharm 
73 Diclofenac Na 15307-86-5 Fluka C14H11Cl2N1O2 4.00 4.02 n - 4.22 2.26 2.03 Pharm 
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74 Diethyl Phthalate 84-66-2 Fluka C12H14O4 NA NA n n 2.69 2.69 1.71 Industrial 
75 Dimethachlor 50563-36-5 Sigma C13H18ClNO2 16.77 2.33 n n 2.59 2.59 2.00 Pesticide 
76 Dimethoate 60-51-5 Fluka C5H12NO3PS2 15.93 0.28 n n -1.48 -1.48 1.58 Pesticide 
77 Diphenhydramine HCl 58-73-1 Fluka C17H21NO 8.87 3.11 + + 0.15 0.87 2.19 Pharm 
78 Diuron 330-54-1 Fluka C9H10Cl2N2O1 13.18 2.67 n n 2.30 2.30 1.60 Pesticide 
79 Efavirenz 154598-52-4 Sigma C14H9ClF3NO2 -1.49 4.15 n n 4.45 1.89 1.89 Pharm 
80 Estrone 53-16-7 Fluka C18H22O2 10.33 3.43 n n 4.31 4.31 2.16 Hormone 
81 Ethofumesate 26225-79-6 Fluka C13H18O5S1 NA 1.51 n n 2.34 2.34 2.05 Pesticide 
82 Ethyl butylacetyl amnopropionate 52304-36-6 Aldrich C11H21NO3 -1.29 1.51 n n 0.96 0.96 1.85 Pesticide 
83 Famciclovir 104227-87-4 Sigma C14H19N5O4 -1.96 0.64 n n -3.46 -1.51 2.34 Pharm 
84 Famotidine 76824-35-6 Fluka C8H15N7O2S3 1.74 -0.65 + + -5.07 -2.96 2.26 Pharm 
85 Fexofenadine HCl 83799-24-0 Sigma C32H39NO4 4.04 NA + z 2.32 2.94 4.09 Pharm 
86 Fluconazole 86386-73-4 Fluka C13H12F2N6O 1.70 0.25 n n 0.49 0.56 2.01 Pharm 
87 Fluoxetine HCl 54910-89-3 Fluka C17H18F3NO 9.80 4.65 + + 0.93 1.04 2.24 Pharm 
88 Folic Acid 59-30-3 Sigma C19H19N7O6 2.09 -2.81 n - -1.59 -4.68 3.04 Natural 
89 Furosemide 54-31-9 Cerilliant C12H11ClN2O5S -1.52 2.32 n - 1.72 0.00 2.10 Pharm 
90 Gabapentin 60142-96-3 Sigma C9H17NO2 4.63 -1.37 + z -2.00 -1.29 1.44 Pharm 
91 Gemfibrozil 25812-30-0 Fluka C15H22O3 4.42 4.77 n - 4.37 2.80 2.12 Pharm 
92 Gibberellic Acid 77-06-5 Sigma C19H22O6 -0.90 0.45 n - 0.32 -1.48 2.42 Pesticide 
93 Hexamethylphosphoramide 680-31-9 Sigma C6H18N3OP -0.12 -0.22 n n -1.41 -1.40 1.52 Industrial 
94 Hexazinone 51235-04-2 Sigma C12H20N4O2 -1.24 2.15 n n 1.37 1.37 1.97 Pesticide 
95 Hydrochlorothiazide 58-93-5 Sigma C7H8ClN3O4S2 9.09 -0.10 n n -0.58 -0.58 1.73 Pharm 
96 Hydrocodone 125-29-1 Cerilliant C18H21NO3 8.61 2.16 + + -1.54 -0.59 2.21 Pharm 
97 Hydrocortisone 50-23-7 Sigma C21H30O5 12.59 1.62 n n 1.28 1.28 2.80 Pharm 
98 Ibuprofen 15687-27-1 USP C13H18O2 4.85 3.79 n - 3.84 2.67 1.78 Pharm 
99 Imidacloprid 138261-41-3 Fluka C9H10ClN5O2 -0.40 -0.41 z z -0.95 1.02 1.68 Pesticide 
100 Iodocarb 55406-53-6 Fluka C8H12INO2 14.40 2.45 n n 3.19 0.68 1.58 Pesticide 
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101 Iopromide 73334-07-3 Sigma C18H24I3N3O8 -2.31 NA n n 0.48 -2.31 3.82 Pharm 
102 Ioxynil 1689-83-4 Fluka C7H3I2NO 2.85 3.94 n - 3.38 2.85 1.45 Pesticide 
103 Irbesartan 138402-11-6 Sigma C25H28N6O 5.13 5.31 + - 4.37 5.13 3.32 Pharm 
104 Isophorone Diisocyanate 4098-71-9 Sigma C12H18O2N2 2.13 4.75 n n 2.13 2.13 1.84 Industrial 
105 Isoproturon 34123-59-6 Fluka C12H18N2O1 2.57 2.84 n n 2.57 2.57 1.78 Pesticide 
106 Ketamine HCl 6740-88-1 Cerilliant C13H16ClNO 7.16 3.12 + + 0.15 2.16 1.83 Pharm 
107 Ketoprofen 22071-15-4 Fluka C16H14O3 3.88 3.00 n - 3.56 1.51 1.98 Pharm 
108 Lamotrigine 84057-84-1 Sigma C9H7Cl2N5 5.87 0.99 + n -0.59 1.10 1.65 Pharm 
109 Levetiracetam 102767-28-2 Sigma C8H14N2O2 -1.56 -0.49 n n -2.42 -2.42 1.36 Pharm 
110 Lidocaine 137-58-6 Fluka C14H22N2O 7.75 1.66 + + 0.51 0.92 2.06 Pharm 
111 Linuron 330-55-2 Fluka C9H10Cl2N2O2 11.94 2.91 n n 2.30 2.30 1.66 Pesticide 
112 Losartan Potassium 114798-26-4 Sigma C22H23ClN6O -1.45 4.01 + - 4.22 4.72 3.12 Pharm 
113 Mabuterol HCl 56341-08-3 Sigma C13H18ClF3N2O 0.90 2.32 + + -0.64 -0.48 2.14 Pharm 
114 MCPA 94-74-6 Fluka C9H9ClO3 3.36 2.52 n - 2.25 -0.17 1.39 Pesticide 
115 Mecoprop 93-65-2 Fluka C10H11ClO3 3.47 2.94 n - 2.85 0.49 1.54 Pesticide 
116 Meprobamate 57-53-4 Cerilliant C9H18N2O4 15.17 0.98 n n -2.79 -2.79 1.73 Pharm 
117 Metalaxyl 57837-19-1 Sigma C15H21NO4 15.80 1.70 n n 2.12 2.12 2.23 Pesticide 
118 Metamitron 41394-05-2 Fluka C10H10N4O1 2.78 1.44 n n 0.24 0.44 1.50 Pesticide 
119 Metaxalone 1665-48-1 Cerilliant C12H15NO3 13.14 2.60 n n 3.09 1.26 1.69 Pharm 
120 Metformin HCl 657-24-9 Fluka C4H11N5 -1.55 -1.40 + + -5.75 -5.74 1.09 Pharm 
121 Methadone 76-99-3 Cerilliant C21H27NO 9.12 4.17 + + 1.51 2.04 2.71 Pharm 
122 Methocarbamol 532-03-6 Fluka C11H15NO5 13.60 -0.26 n n -1.41 -1.41 1.77 Pharm 
123 Methomyl 16752-77-5 Fluka C5H10N2O2S 0.69 0.61 n n 1.39 -0.96 1.21 Pesticide 
124 Metolachlor 51218-45-2 Fluka C15H22ClNO2 16.75 3.24 n n 3.45 3.45 2.28 Pesticide 
125 Metolachlor-ESA 171118-09-5 Sigma C15H23N1O5S1 -0.68 1.69 - - -0.24 -0.26 2.50 Pesticide 
126 Metoprolol Tartrate 37350-58-6 Fluka C15H25NO3 9.67 1.69 + + -1.48 -1.34 2.26 Pharm 
127 Metribuzin 21087-64-9 Fluka C8H14N4OS 2.46 1.49 n n 1.85 1.96 1.62 Pesticide 
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128 Metsulfuron-methyl 74223-64-6 Sigma C14H15N5O6S 0.22 2.00 n - 0.54 -0.53 2.53 Pesticide 
129 Molinate 2212-67-1 Fluka C9H17NOS NA 2.91 n n 2.34 2.34 1.55 Pesticide 
130 Morphine 57-27-2 Cerilliant C17H19NO3 9.12 0.72 + + -2.30 -1.83 2.06 Pharm 
131 N,N-didesmethylvenlafaxine 93413-77-5 TRC C15H23N1O2 -0.96 2.60 + + -1.10 -0.96 2.09 Pharm 
132 N4-acetylsulfamethoxazole 21312-10-7 Sigma C12H13N3O4S -0.11 1.21 n - 1.57 -0.11 2.02 Pharm 
133 Nadolol 42200-33-9 Fluka C17H27NO4 -2.26 1.17 + + -2.38 -2.26 2.49 Pharm 
134 Naproxen 22204-53-1 USP C14H14O3 1.18 3.10 n - 2.96 1.18 1.78 Pharm 
135 Nicotine 54-11-5 Fluka C10H14N2 -1.37 1.00 + + -2.49 -1.37 1.37 Drug 
136 Norfloxacin 70458-96-7 Sigma C16H18FN3O3 -1.06 -0.31 + z -1.79 -1.06 2.27 Pharm 
137 Ofloxacin 82419-36-1 Sigma C18H20FN3O4 5.45 -2.00 + z -1.38 0.65 2.50 Pharm 
138 Oxazepam 604-75-1 Cerilliant C15H11ClN2O2 -1.47 3.34 n n 1.95 0.15 1.99 Pharm 
139 Oxcarbazepine 28721-07-5 Fluka C15H12N2O2 13.18 1.11 n n 2.29 1.61 1.87 Pharm 
140 Oxybenzone 131-57-7 Fluka C14H12O3 7.07 3.52 n n 3.62 3.59 1.74 Lifestyle 
141 Paraxanthine 611-59-6 Cerilliant C7H8N4O2 -1.10 -0.39 n n -0.17 -2.72 1.22 Lifestyle 
142 Penciclovir 39809-25-1 Sigma Aldrich C10H15N5O3 2.59 -3.71 n n -3.81 -3.03 1.80 Pharm 
143 Pentoxyfylline 6493-05-6 Sigma C13H18N4O3 -1.16 0.56 n n 0.23 0.23 2.08 Pharm 
144 Perfluoroctanoic acid (PFOA) 335-67-1 Aldrich C8HF15O2 -4.20 6.30 - - 1.58 1.58 1.58 Industrial 
145 Phenobarbital 50-06-6 Cerilliant C12H12N2O3 7.14 1.33 n n -0.35 -4.48 1.70 Pharm 
146 Phenytoin (Dilantin) 57-41-0 Fluka C15H12N2O2 8.49 2.16 n n 2.62 -1.53 1.87 Pharm 
147 Pirimicarb 23103-98-2 Fluka C11H18N4O2 4.99 1.40 + n 0.13 1.76 1.89 Pesticide 
148 Pirimiphos-Ethyl 23505-41-1 Sigma C12H14N2O2 5.09 4.42 + n 1.97 3.63 2.55 Pesticide 
149 Primidone 125-33-7 Fluka C13H24N3O3PS 11.50 0.73 n n 1.66 -0.92 1.68 Pharm 
150 Progesterone 57-83-0 Sigma Aldrich C21H30O2 NA 3.67 n n 4.15 4.15 2.62 Hormone 
151 Prohexadione Calcium 127277-53-6 Sigma C10H12O5 3.42 1.06 n - 0.76 -1.23 1.52 Pesticide 
152 Prometon 1610-18-0 
Sigma 
Aldrich-
Fluka 
C10H19N5O -1.66 3.57 + n -1.03 -0.70 1.84 Pesticide 
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153 Propachlor 1918-16-7 Fluka C11H14ClNO 16.77 2.42 n n 2.39 2.39 1.66 Pesticide 
154 Propachlor ESA Na 123732-85-4 
Sigma 
Aldrich-
Fluka 
C11H15N1O4S1 -0.88 0.87 - - -1.32 -1.33 1.86 Pesticide 
155 Propachlor OXA 70628-36-3 
Sigma 
Aldrich-
Fluka 
C11H13N1O3 3.03 0.60 n - 1.51 -1.06 1.61 Pesticide 
156 Propazine 139-40-2 Sigma C9H16ClN5 3.17 3.24 n n -0.50 1.52 1.76 Pesticide 
157 Propoxur 114-26-1 Sigma C11H15NO3 14.76 1.90 n n 2.66 0.62 1.65 Pesticide 
158 Propranolol HCl 525-66-6 Fluka C16H21NO2 9.67 2.60 + + -0.66 -0.52 2.15 Pharm 
159 Propyzamide 23950-58-5 Fluka C12H11Cl2NO -1.52 3.57 n n 4.00 3.95 1.84 Pesticide 
160 Pseudoephedrine 299-42-3 Cerilliant C10H15NO 9.52 0.68 + + -1.92 -1.74 1.44 Pharm 
161 Pyrazophos 13457-18-6 Sigma C14H20N3O5PS -0.58 3.53 n n 3.14 3.14 2.61 Pesticide 
162 Ranitidine HCl 66357-35-5 USP C13H22N4O3S 7.12 0.29 z z -2.82 -0.81 2.40 Pharm 
163 Ritalinic Acid 19395-41-6 Sigma C13H17NO2 3.73 -1.07 + z -0.89 -0.36 1.77 Pharm 
164 Serotonin HCl 153-98-0 Sigma C10H12N2O 9.31 0.79 + + -1.85 -1.76 1.39 Natural 
165 Siduron 1982-49-6 Fluka C14H20N2O 13.56 3.86 n n 2.99 2.99 1.95 Pesticide 
166 Simazine 122-34-9 Fluka C7H12ClN5 3.23 2.40 + n -1.37 0.58 1.48 Pesticide 
167 Sitagliptin 486460-32-6 Enamine C16H15F6N5O 0.66 1.39 + + -1.78 -1.33 2.44 Pharm 
168 Sucralose 56038-13-2 USP C12H19Cl3O8 11.91 -1.00 n n -0.47 -0.47 2.42 Lifestyle 
169 Sulfadimethoxine 122-11-2 Fluka C12H14N4O4S 1.95 1.17 n n 1.22 1.22 2.12 Pharm 
170 Sulfamethazine 57-68-1 Sigma C12H14N4O2S -1.97 0.76 n n 0.61 0.61 2.00 Pharm 
171 Sulfamethoxazole 723-46-6 USP C10H11N3O3S 0.25 0.48 n n 0.75 0.60 1.72 Pharm 
172 Sulfathiazole 72-14-0 Fluka C9H9N3O2S2 0.35 0.72 n n 0.93 0.93 1.69 Pharm 
173 TDCPP 13674-87-8 Sigma C9H15Cl6O4P NA 3.65 n n 4.28 4.28 2.55 Industrial 
174 Temazepam 846-50-4 Cerilliant C16H13ClN2O2 -1.40 2.15 n n 2.79 2.79 2.13 Pharm 
175 Terbutylazine 5915-41-3 Fluka C9H16ClN5 3.18 3.27 n n -0.42 -0.35 1.76 Pesticide 
176 Testosterone 58-22-0 Cerilliant C19H28O2 -0.88 3.27 n n 3.37 3.37 2.38 Hormone 
177 Theophylline 58-55-9 Fluka C7H8N4O2 -0.78 -0.39 n n -0.90 -0.81 1.22 Pharm 
178 Thiabendazole 148-79-8 Fluka C10H7N3S -0.22 2.00 + n 1.38 2.32 1.40 Pharm 
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179 cis-Tramadol HCl 27203-92-5 Cerilliant C16H25NO2 9.23 3.01 + + -1.05 -0.59 2.23 Pharm 
180 Triamterene 396-01-0 Sigma C12H11N7 1.86 0.80 n n -2.22 -1.44 1.83 Pharm 
181 Tributyl phosphate (TBP) 126-73-8 Fluka C12H27O4P NA 3.82 n n 4.09 4.09 2.24 Industrial 
182 Triclosan 3380-34-5 Aldrich C12H7Cl3O2 7.68 4.66 n n 4.98 4.97 1.81 Pesticide 
183 Trimethoprim 738-70-5 USP C14H18N4O3 -0.90 0.73 + + -3.92 -2.35 2.18 Pharm 
184 Trinexapac-ethyl 95266-40-3 Fluka C13H16O5 4.56 0.63 n - 0.75 -1.67 1.84 Pesticide 
185 Tris (2-chloro-ethyl) phosphate (TCEP) 115-96-8 Aldrich C6H12Cl3O4P NA 1.63 n n 2.11 2.11 1.76 Industrial 
186 Valsartan 137862-53-4 USP C24H29N5O3 -1.52 3.65 n - 5.25 3.27 3.41 Pharm 
187 Venlafaxine HCl 93413-69-5 USP C17H27NO2 8.91 3.28 + + -0.76 -0.07 2.37 Pharm 
188 Verapamil HCl 52-53-9 Fluka C27H38N2O4 9.68 4.80 + + 1.54 1.76 3.79 Pharm 
189 Warfarin 2610-86-8 Fluka C19H16O4 5.56 2.23 n - 2.72 2.17 2.28 Pesticide 
190 1-Naphthol 90-15-3 Sigma C10H8O 9.60 2.69 n n 2.76 2.76 1.14 Pesticide 
191 Bisphenol A 80-05-7 Fluka C15H16O2 9.78 3.64 n n 4.32 4.32 1.86 Industrial 
192 2-amino-5-chlorothiazole HCl 55506-37-1 Sigma C3H4Cl2N2S 3.91 NA + n NA NA 0.82 Pesticide 
193 2-aminothiazole 96-50-4 Sigma C3H4N2S 5.09 0.83 + n -0.70 0.48 0.70 Pesticide 
194 3-amino-5-methylisoxazole 1072-67-9 Sigma C4H6N2O 2.44 -0.16 n n 0.37 0.48 0.74 Pesticide 
195 4-aminophenol 123-30-8 Sigma C6H7NO 5.43 0.24 + n -1.40 0.88 0.87 Industrial 
196 Acyclovir 59277-89-3 Fluka C8H11N5O3 2.63 -4.27 n n -1.85 -1.85 1.52 Pharm 
197 Aldicarb 116-06-3 Fluka C7H14O2N2S 1.63 1.36 n n 1.97 -0.16 1.49 Pesticide 
198 Allopurinol 315-30-0 Fluka C5H4N4O -0.45 -1.14 n n 0.35 0.34 0.88 Pharm 
199 Astemizole 68844-77-9 Sigma C28H31FN4O 6.24 6.43 + + 0.23 1.66 3.56 Pharm 
200 Atorvastatin Ca 134523-00-5 Fluka C33H35FN2O5 4.31 NA n - 6.09 3.58 4.28 Pharm 
201 Benzoic Acid 65-85-0 Fisher C7H6O2 4.08 1.87 n - 1.60 -0.29 0.93 Pesticide 
202 Benzophenone 119-61-9 Supelco C13H10O NA 3.15 n n 3.43 3.43 1.48 Lifestyle 
203 Bifenazate 149877-41-8 Fluka C17H20N2O3 13.69 4.14 n n 4.67 2.87 2.36 Pesticide 
204 Bupropion HCl 34841-39-9 Cerilliant C13H18ClNO 8.22 3.85 + + 0.03 1.09 1.94 Pharm 
205 Butalbital 77-26-9 Cerilliant C11H16N2O3 7.48 1.87 n n 0.65 -3.85 1.75 Pharm 
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206 Butocarboxim 34681-10-2 Sigma C7H14N2O2S 1.33 1.21 n n 2.04 -0.10 1.49 Pesticide 
207 Carbamazepine-10,11 -epoxide 36507-30-9 Sigma C15H12N2O2 15.96 0.95 n n 2.03 1.83 1.80 Pharm 
208 Carbaryl 63-25-2 Fluka C12H11NO2 14.77 2.35 n n 2.96 1.33 1.54 Pesticide 
209 Carbazole 86-74-8 Fluka C12H9N 14.97 3.29 n n 3.09 3.09 1.32 Industrial 
210 Catechol (1,2-dihydroxybenzene) 120-80-9 Sigma C6H6O2 9.34 1.03 n n 1.37 1.37 0.83 Natural 
211 Chloroxylenol 88-04-0 Fluka C8H9ClO 9.21 NA n n 3.30 3.30 1.18 Pesticide 
212 Chlorpheniramine Maleate 132-22-9 Fluka C16H19ClN2 3.57 3.82 + + -0.54 0.40 2.21 Pharm 
213 Citric Acid 77-92-9 Sigma C6H8O7 3.05 -1.67 n - -1.60 -6.20 1.24 Pesticide 
214 DI-tert-butyl dicarbonate 24424-99-5 Sigma C10H18O5 NA 1.87 n n 2.53 2.53 1.73 Pesticide 
215 Diazepam 439-14-5 Sigma C16H13ClN2O 2.92 2.70 n n 1.09 2.75 2.07 Pharm 
216 Diazinon 333-41-5 Fluka C12H21N2O3PS 4.19 3.86 + n 3.00 4.19 2.31 Pesticide 
217 Dikegulac 52508-35-7 Sigma C12H18O7 3.05 1.76 n - NA NA 1.84 Pesticide 
218 Emtricitabine 143491-57-0 TRC C8H10FN3O3S 14.29 -2.56 n n 0.07 0.07 1.55 Pharm 
219 Epinephrine 51-43-4 Sigma C9H13NO3 8.91 -0.69 + + -3.28 -3.28 1.42 Pharm 
220 Erythromycin 114-07-8 Fluka C37H67NO13 8.38 NA + + -0.90 0.25 5.77 Pharm 
221 17α-Estradiol 57-91-0 Sigma C18H24O2 -0.88 3.94 n n 3.71 3.71 2.20 Hormone 
222 Estriol 50-27-1 Fluka C18H24O3 10.33 2.81 n n 2.67 2.67 2.26 Hormone 
223 17α-Ethynyl-estradiol 57-63-6 Fluka C20H24O2 -1.66 4.12 n n 3.72 3.72 2.39 Pharm 
224 Flucytosine 2022-85-7 Sigma C4H4FN3O 8.31 -1.42 n n -1.29 -0.42 0.81 Pharm 
225 Glyphosate 1071-83-6 Fluka C3H8NO5P -0.58 -4.47 z z -3.71 -6.53 1.09 Pesticide 
226 Histamine 51-45-6 Sigma C5H9N3 7.14 -0.73 + + -5.66 -4.90 0.92 Natural 
227 Indole 120-72-9 Sigma C8H7N 16.44 2.05 n n 2.15 2.15 0.95 Pesticide 
228 Lamivudine 134678-17-4 Sigma C8H11N3O3S 0.21 -2.62 n n -0.33 -0.27 1.53 Pharm 
229 Malaoxon 1634-78-2 Fluka C10H19O7PS NA 0.52 n n 0.97 0.97 2.21 Pesticide 
230 Melamine 108-78-1 Sigma C3H6N6 1.84 -0.38 + + -7.88 -5.95 0.89 Industrial 
231 Meptyldinocap 131-72-6 Sigma C18H24N2O6 NA 5.90 n n 6.30 6.30 2.79 Pesticide 
232 Metaldehyde 108-62-3 Sigma C8H16O4 NA 0.85 n n 0.86 0.86 1.36 Pesticide 
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233 Nitrosobenzene 586-96-9 Fluka C6H5NO 1.61 1.86 n n 1.82 1.82 0.83 Natural 
234 Nonylphenol 84852-15-3 Fluka C15H24O 10.31 5.92 n n 5.33 5.33 2.04 Industrial 
235 Paraquat dichloride hydrate 1910-42-5 Sigma C12H14Cl2N2 -7.00 NA z z -6.70 -6.70 1.54 Pesticide 
236 Pentobarbital 76-74-4 Cerilliant C11H18N2O3 7.48 2.00 n n 1.86 1.85 1.80 Pharm 
237 Perfluorobutanoic acid (PFBA) 375-22-4 Aldrich C4HF7O2 1.07 2.43 - - 0.38 -1.20 0.87 Industrial 
238 Phthalimide 85-41-6 Sigma C8H5NO2 8.40 1.30 n n 0.38 0.38 1.02 Pesticide 
239 Propofol 2078-54-8 Cerilliant C12H18O 10.98 3.57 n n 4.15 4.15 1.62 Pharm 
240 Sertraline HCl 79617-96-2 Cerilliant C17H17Cl2N 9.56 5.29 + + 1.91 2.08 2.26 Pharm 
241 Sulfanilic Acid 121-57-3 Sigma C6H7NO3S -3.39 -2.08 - - -1.44 -2.20 1.16 Industrial 
242 β-Estradiol 50-28-2 Sigma C18H24O2 -0.88 3.94 n n 3.71 3.71 2.20 Hormone 
a. Number is used for further reference. Compounds with number from 190 (1-Naphthol) to 242 (β-Estradiol) are compounds that either cannot be detected or cannot be quantified 
well using the instrumental analysis method adopted in this research; 
b. “TRC” stands for Toronto Research Chemicals; 
c. All pKa values are the lowest pKa obtained from Marvin from ChemAxon; 
d. All Log Kow are adopted from Chemspider website (http://www.chemspider.com), which are estimated values reported by the KOWWIN package in the EPIsuite software; 
e. All LogD data and charge state of major microspecies are estimated data predicted by Marvin from ChemAxon; 3 and 6 are pH values; “+” represents cations, “-” represents 
anions, “n” represents neutral species and “z” represents zwitters; “NA” stands for Not Applicable; 
f. “MV” stands for McGowan volume, units in cm3 mol-1; all MV data are obtained from ufz database; 
g. “Pharm” stands for pharmaceuticals; “Drug” means illicit drugs.
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Table A2. Chemicals and solvents. 
 
Substance CAS No. Supplier 
Acetone (HPLC Purity) 67-64-1 Sigma-Aldrich 
Ammonia7N 7664-41-7 Fisher Scientific 
Ammonium Acetate, ≥98% 631-61-8 Sigma-Aldrich 
Formic Acid, 14N 64-18-6 Acros-Sigma 
Methanol (HPLC Purity) 67-56-1 Fisher Scientific 
Nitrogen Gas (>99%) NA AirGas 
Oasis HLB (60µm; 20 cc Vac Cartridge) NA Waters 
Sodium Chloride 7647-14-5 Fisher Scientific 
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Table A3.  Information on 44 isotope labeled internal standards (ILIS). 
No. Internal Standard CAS No. Supplier 
1 2-methyl-3-isothiazolinone-d3 HCl 1329509-49-0 TRC 
2 Acetaminophen-ring-d4 64315-36-2 Aldrich 
3 Allopurinol-d2 916979-34-5 TRC 
4 Atenolol-d7 1202864-50-3 Aldrich 
5 Atrazine-d5, 99.7% 163165-75-1 Aldrich 
6 Azoxystrobin-d4 1346606-39-0 TRC 
7 Caffeine-13C3 200-659-6 Aldrich 
8 Carbamazepine-13C6 Not available Aldrich 
9 Carbaryl-d7 362049-56-7 TRC 
10 Carbofuran-d3 1007459-98-4 Aldrich 
11 Celecoxib-d4 544686-20-6 TRC 
12 Cimetidine-d3 1185237-29-9 TRC 
13 Citalopram-d66 1246819-94-2 TRC 
14 Dextromethorphan-d3 524713-56-2 TRC 
15 Diclofenac-(acetophenyl ring-13C6) sodium salt hemi(nonahydrate), 99.9% 1261393-73-0 Aldrich 
16 Diltiazem-d4 HCl Not available TRC 
17 Dimethoate-d6 1219794-81-6 TRC 
18 rac-Efavirenz-d4 1246812-58-7 TRC 
19 Erythromycin-13C,d3 959119-26-7 TRC 
20 Estrone-d2 56588-58-0 TRC 
21 Fexofenadine-d6 548783-71-7 TRC 
22 Fluoxetine-d5 1173020-43-3 Aldrich 
23 Gemfibrozil-d6 Not available TRC 
24 Ibuprofen-d3, ≥ 98% 121662-14-4 Aldrich 
25 Imidacloprid-d4 1015855-75-0 Aldrich 
26 Iodocarb-d9 1246815-08-6 TRC 
27 Iopromide-d3 1189947-73-6 TRC 
28 Isoproturon-d6 217487-17-7 Aldrich 
29 Mecoprop-d3 352431-15-3 TRC 
30 Metformin-d6 HCl 1185166-01-1 TRC 
31 Metoprolol Acid-d5 Not available TRC 
32 Morphine-d3 118357-24-7 Aldrich 
33 Naproxen-(methoxy)-d3 958293-79-3 Fluka 
34 Oxybenzone-d3 Not available TRC 
35 Pirimicarb-d6 1015854-66-6 Aldrich 
36 Ranitidine-d6 1185238-09-8 TRC 
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37 Sucralose-d6 Not available TRC 
38 Sulfadimethoxine-d6, 99.4% 73068-02-7 Aldrich 
39 Sulfamethoxazole-(phenyl-13C6), 99.5% 1196157-90-0 Aldrich 
40 Thiabendazole-d4 1190007-20-5 TRC 
41 Triclosan-d3 1020719-98-5 TRC 
42 Trimethoprim-d9, 99.9% 1189460-62-5 Aldrich 
43 Tris(2-chloroethyl)phosphate-d12 1276500-47-0 TRC 
44 Venlafaxine-D6 HCl 1062606-12-5 Aldrich 
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Appendix B - Analytical Information of Targeted Compounds 
Table B1. Analytical information for 189 target compounds. 
No. Compound Name 
Exact 
Mass  
[M] 
Ionization  
Modea 
Offline  
SPE 
RTb 
Offline  
LODc 
Online  
SPE 
RTb 
Onlin
e  
LODc 
Fragmentd 
Internal Standard Mass Formula 
1 10,11-dihydrocarbamazepine 238.1101 Positive 7.02 1 12.52 5 194.0967 C14H12N Carbamazepine 
2 2-aminobenzimidazole 133.0635 Positive 2.67 5 8.26 100 92.0498 C6H6N Iopromid 
3 2-ethyl-2-phenyl  
malonamide monohydrate 206.1055 Positive 3.35 25 9 100 119.0856 C9H11 Iopromid 
4 2-mercaptobenzothiazole 166.9858 Positive 6.1 1 11.6 5 135.0138 C7H5NS Carbofuran 
5 2-methyl-4-isothiazolin- 
3-one (MI) 115.0086 Positive 1.57 1 7.1 500 88.076 C3H6NS 
2-
methylisothiazolinon-
3-one 
6 2,4-D 219.9689 Negative 8.1 5 13.74 25 160.9556 C6H3OCl2 Mecoprop 
7 2,6-dichlorobenzamide 188.9748 Positive 3.5 5 9.1 100 172.9557 C7H3OCl2 Dimethoate 
8 2,6-dimethoxyphenol 154.0630 Positive 4.7 50 10.45 NA 95.0494 C6H7O Erythromycin 
9 6-benzylaminopurine 225.1009 Positive 4.6 1 10.25 10 148.0620 C6H6N5 Dimethoate 
10 Abacavir 286.1542 Positive 3.35 5 8.88 5 191.1041 C8H11N6 Sulfamethoxazole 
11 Abscisic Acid 264.1356 Positive 6.13 1 11.4 100 187.1120 C13H15O Carbofuran 
12 Acebutolol HCl 336.2044 Positive 4.4 1 9.65 5 319.2014 C18H27O3N2 Atenolol 
13 Acephate 183.0114 Positive 2.1 5 7.55 1000 142.9928 C2H8O3PS Acetaminophen 
14 Acesulfame K 200.9493 Negative 1.7 5 7.3 1500 82.0285 C4H4ON Mecoprop 
15 Acetaminophen 151.0628 Positive 2.3 5 7.95 250 110.0602 C6H8ON Acetaminophen 
16 Acetamiprid 222.0667 Positive 4.45 5 10.07 50 144.0212 C4H5N4Cl Dimethoate 
17 Acetazolamide 221.9876 Positive 2.56 5 8.01 NA 181.9690 C2H4O3N3S2 Iopromid 
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18 Acetochlor 269.1177 Positive 10.3 5 15.9 10 162.1278 C11H16N Celecoxib 
19 Adrenalone HCl 181.0734 Positive 1.1 25 6.4 1000 146.0601 C9H8ON Metformin 
20 Adrenosterone 300.1725 Positive 6.55 1 11.97 10 257.1536 C17H21O2 Carbofuran 
21 Alachlor 269.1177 Positive 10.3 5 15.9 10 162.1278 C11H16N Celecoxib 
22 Albuterol 239.1521 Positive 2.18 1 7.68 100 148.0758 C9H10ON Iopromid 
23 Amicinonide 502.2361 Positive 11.9 5 17.32 10 321.1486 C21H21O3 Ibuprofen_Na 
24 Amisulpride 369.1717 Positive 3.21 1 8.71 25 242.0483 C10H12O4NS Metoprolol Acid 
25 Amitriptyline HCl 277.1830 Positive 7.75 1 12.97 5 233.1325 C18H17 Fluoxetine 
26 Amphetamine 135.1048 Positive 3.3 5 8.84 50 91.0545 C7H7 Venlafaxine 
27 Ampicillin 349.1091 Positive 4.17 25 9.69 50 192.0477 C10H10ONS Pirimicarb 
28 Arecoline HBr 155.0941 Positive 1.22 5 6.46 750 81.0340 C5H5O Metformin 
29 Atenolol 266.1625 Positive 2.3 1 7.68 50 190.0863 C11H12O2N Atenolol 
30 Atenolol Acid 267.1471 Positive 3.3 5 8.8 10 191.0705 C11H11O3 Metoprolol Acid 
31 Atomexine HCl 255.1618 Positive 7.05 1 12.36 10 224.0840 C15H14ON Atrazine 
32 Atrazin-2-Hydroxy 197.1271 Positive 3.8 1 9.32 5 156.0882 C5H10ON5 Sulfamethoxazole 
33 Atrazin-desethyl 187.0619 Positive 4.8 1 10.58 5 146.0229 C3H5N5Cl Dimethoate 
34 Atrazine 215.0932 Positive 7.3 1 12.79 0.5 174.0542 C5H9N5Cl Atrazine 
35 Atrazine-desethyl- 
desisopropyl 145.0155 Positive 1.7 25 7.7 NA 104.0011 C2H3N3Cl Metformin 
36 Atropine 289.1673 Positive 3.72 1 9.24 5 260.1645 C16H22O2N Sulfamethoxazole 
37 Azoxystrobin 403.1163 Positive 8.7 1 14.17 5 372.0980 C21H14O4N3 Azoxystrobin 
38 Baclofen 213.0551 Positive 3.5 5 9.12 50 151.0311 C9H8Cl Thiabendazole 
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39 Bendiocarb 223.0839 Positive 6.17 5 11.68 10 167.0703 C9H11O3 Tris (2-chloro-ethyl) phosphate 
40 Bentazon 240.0563 Negative 6.6 5 12.12 5 175.0867 C10H11ON2 Triclosan 
41 Benzisothiazolin-3-on  
(BIT) 151.0086 Positive 4.4 5 10.1 10 109.0108 C6H5S Dimethoate 
42 Benzotriazole 119.0478 Positive 3.9 1 9.58 10 92.0497 C6H6N Sulfamethoxazole 
43 Benzotriazole-methyl-1H 133.0635 Positive 5.1 1 10.7 5 106.0652 C7H8N Fexofenadine 
44 Benzoylecgonine 289.1309 Positive 4 1 9.58 0.5 168.1020 C9H14O2N Imidacloprid 
45 Bis(2-ehtylhexyl)  
phthalate 390.2770 Positive 18.3 1 24.06 NA 313.2050 C24H25 Celecoxib 
46 Bromacil 260.0155 Positive 6.1 25 11.66 10 204.9610 C5H6O2N2Br Erythromycin 
47 Caffeine 194.0798 Positive 3.4 25 9.04 100 138.0664 C6H8ON3 Caffeine 
48 Candesartan 440.1592 Positive 8.15 1 13.63 5 263.1292 C16H15N4 Fluoxetine 
49 Carbamazepine 236.0944 Positive 6.6 1 12.12 5 194.0966 C14H12N Carbamazepine 
50 Carbendazim 191.0690 Positive 3.06 1 8.62 10 160.0507 C8H6ON3 Iopromid 
51 Carbofuran 221.1057 Positive 6.05 25 11.61 10 165.0912 C10H13O2 Carbofuran 
52 Carisoprodol 260.1736 Positive 7.6 5 13.07 25 158.1176 C8H16O2N Atrazine 
53 Celecoxib 381.0759 Positive 10.85 5 16.36 10 362.0769 C17H14O2M3F2S Celecoxib 
54 Chloridazon 221.0350 Positive 4.5 1 10.23 10 128.9851 C4H2ON2Cl Imidacloprid 
55 Cimetidine 252.1157 Positive 2.3 5 7.83 100 159.0700 C5H11N4S Cimetidine 
56 Ciprofloxacin 331.1327 Positive 3.78 5 9.2 NA 288.1506 C18H19ON3F Sulfamethoxazole 
57 cis-diltiazem 414.1613 Positive 6.4 1 11.69 5 310.1695 C14H19O2N2PS Diltiazem 
58 Citalopram HBr 324.1638 Positive 5.9 1 11.19 5 262.1026 C18H13NF Citalopram 
59 Clarithromycin 747.4764 Positive 8.75 5 13.93 25 590.3900 C30H56O10N Azoxystrobin 
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60 Climbazole 292.0973 Positive 7 1 12.39 5 197.0730 C11H14OCl Atrazine 
61 Clofibric Acid 214.0391 Negative 8.9 5 14.4 10 126.9944 C6H4OCl Mecoprop 
62 Codeine 299.1521 Positive 2.52 1 8 100 215.1068 C14H15O2 Iopromid 
63 Corticosterone 346.2139 Positive 8.2 5 13.43 5 329.2113 C21H29O3 Azoxystrobin 
64 Cotinine 176.0950 Positive 1.2 1 6.5 750 146.0602 C9H8ON Metformin 
65 Coumarin 146.0363 Positive 4.92 25 10.65 5 91.0545 C7H7 Sulfadimethoxine 
66 Cyanazine 240.0885 Positive 5.67 25 11.1 25 214.0855 C8H13N5Cl Venlafaxine 
67 Cyflufenamid 412.1205 Positive 12.2 5 17.72 10 241.0396 C16H5ON2 Ibuprofen_Na 
68 DEET 191.1305 Positive 7.5 1 12.9 0.5 119.0492 C8H7O Fexofenadine 
69 Dehydroacetic Acid 168.0417 Positive 5.03 1 10.8 50 106.9436 C6H3O2 Venlafaxine 
70 Desvenlafaxine 263.1880 Positive 4.24 1 9.7 10 201.1278 C14H17O Sulfamethoxazole 
71 Dexamethasone 392.1999 Positive 8 5 13.42 5 237.1278 C17H17O Carbofuran 
72 Dextromethorphan HBr 271.1936 Positive 5.8 1 11.13 5 215.1432 C15H19O Dextromethorphan 
73 Diclofenac 295.0161 Positive 11.5 25 16.99 10 215.0498 C13H10NCl Diclofenac 
74 Diethyl Phthalate 222.0887 Positive 7.72 1 13.2 25 149.0234 C8H5O3 Isoproturon 
75 Dimethachlor 255.1021 Positive 7.92 1 13.41 5 224.0838 C12H15ONCl Isoproturon 
76 Dimethoate 229.0002 Positive 4.5 1 10.19 10 142.9928 C2H8O3PS Dimethoate 
77 Diphenhydramine HCl 255.1623 Positive 5.95 1 11.26 5 167.0857 C13H11 Citalopram 
78 Diuron 232.0165 Positive 7.9 5 13.44 10 159.9717 C6H4NCl2 Isoproturon 
79 Efavirenz 315.0274 Positive 11.5 25 16.99 10 244.0137 C11H6NClF3 Efavirenz 
80 Estrone 270.1620 Positive 5.8 25 14.57 100 157.0648 C11H9O Estrone 
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81 Ethofumesate 286.0869 Positive 8.9 5 14.33 10 161.0598 C10H9O2 Azoxystrobin 
82 Ethyl butylacetyl  
amnopropionate 215.1521 Positive 6.6 5 12 NA 128.1069 C7H14ON Atrazine 
83 Famciclovir 321.1432 Positive 3.6 5 8.97 10 202.1088 C10H12N5 Thiabendazole 
84 Famotidine 337.0449 Positive 2.3 25 7.77 100 189.0264 C5H9N4S2 Acetaminophen 
85 Fexofenadine HCl 501.2879 Positive 7.35 1 12.62 5 484.2849 C32H38O3N Fexofenadine 
86 Fluconazole 306.1035 Positive 4.5 1 10.07 5 220.0681 C11H8N3F2 Dimethoate 
87 Fluoxetine HCl 309.1335 Positive 8.35 5 13.54 5 265.1587 C16H19OF2 Fluoxetine 
88 Folic Acid 441.1391 Positive 3.3 25 8.8 100 295.0939 C14H11O2N6 Metoprolol Acid 
89 Furosemide 330.0072 Negative 5.7 25 11.2 25 204.9838 C6H6O2N2ClS Sucralose 
90 Gabapentin 171.1254 Positive 3.23 1 8.76 25 137.0963 C9H13O Metoprolol Acid 
91 Gemfibrozil 250.1563 Positive 13.5 5 18.9 25 83.0859 C6H11 Gemfibrozil 
92 Gibberellic Acid 346.1411 Negative 4.55 25 10.4 100 221.1333 C17H17 Sucralose 
93 Hexamethyl- 
phosphoramide 179.1182 Positive 4.67 1 10.18 5 135.0683 C4H12ON2P Dimethoate 
94 Hexazinone 252.1581 Positive 6.1 5 11.59 5 171.0877 C6H11O2N4 Carbofuran 
95 Hydrochlorothiazide 296.9634 Positive 2.33 50 7.9 NA 232.9782 C7H6O3N2ClS Atenolol 
96 Hydrocodone 299.1521 Positive 2.84 5 8.36 50 199.0754 C13H11O2 Ranitidine 
97 Hydrocortisone 362.2093 Positive 7 5 12.38 10 327.1948 C21H27O3 Carbaryl 
98 Ibuprofen 206.1301 Positive 11.9 25 17.4 10 181.9883 C11H4O2N Ibuprofen_Na 
99 Imidacloprid 255.0523 Positive 4 5 9.69 10 175.0980 C9H11N4 Imidacloprid 
100 Iodocarb 280.9907 Positive 7.4 1 12.85 500 164.9199 C3H2I Iodocarb 
101 Iopromide 790.8692 Positive 2.45 50 7.97 NA 572.9014 C15H15O6N2I2 Iopromid 
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102 Ioxynil 370.8299 Negative 8.3 1 13.91 5 230.9186 C6H2ONI Mecoprop 
103 Irbesartan 428.2319 Positive 7.9 1 13.41 5 386.2226 C25H28ON3 Isoproturon 
104 Isophorone  
Diisocyanate 222.1368 Positive 7.02 5 12.5 100 204.9605 C10O2NK Erythromycin 
105 Isoproturon 206.1414 Positive 7.7 1 13.13 5 134.0965 C9H12N Isoproturon 
106 Ketamine HCl 237.0915 Positive 3.9 1 9.47 5 179.0623 C11H12Cl Sulfamethoxazole 
107 Ketoprofen 254.0937 Positive 8.45 1 13.91 10 209.0962 C15H13O Carbofuran 
108 Lamotrigine 255.0073 Positive 4.66 1 10.19 5 210.9825 C9H5N2Cl2 Dimethoate 
109 Levetiracetam 170.1050 Positive 2.75 1 8.33 NA 126.0914 C7H12ON Iopromid 
110 Lidocaine 234.1732 Positive 3.7 1 9.29 10 163.0282 C11H3N2 Iopromid 
111 Linuron 248.0114 Positive 8.9 5 14.43 5 159.9717 C6H4NCl2 Isoproturon 
112 Losartan Potassium 422.1616 Positive 7.9 1 13.35 5 235.0978 C14H11N4 Isoproturon 
113 Mabuterol HCl 310.1054 Positive 4.7 1 10.1 5 237.0403 C9H9N2ClF3 Dimethoate 
114 MCPA 200.0235 Negative 8.5 5 14.02 10 141.0099 C7H6OCl Mecoprop 
115 Mecoprop 214.0391 Negative 9.7 5 15.22 10 141.0101 C7H6OCl Mecoprop 
116 Meprobamate 218.1267 Positive 5.4 5 10.89 25 203.1429 C9H19O3N2 Erythromycin 
117 Metalaxyl 279.1465 Positive 7.6 1 13 5 160.1122 C11H14N Isoproturon 
118 Metamitron 202.0860 Positive 4.3 5 10.01 10 175.0985 C9H11N4 Imidacloprid 
119 Metaxalone 221.1057 Positive 7.05 1 12.57 5 133.1013 C10H13 Atrazine 
120 Metformin 129.1014 Positive 1.1 25 6.23 NA 71.0609 C3H7N2 Metformin 
121 Methadone 309.2093 Positive 7.45 1 12.69 5 265.1587 C19H21O Fluoxetine 
122 Methocarbamol 241.0950 Positive 4.7 5 10.23 10 163.0755 C10H11O2 Erythromycin 
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123 Methomyl 162.0463 Positive 3.15 5 8.73 250 102.9699 C2HO2NS Thiabendazole 
124 Metolachlor 283.1334 Positive 10.5 1 16 1 252.1151 C14H19ONCl Azoxystrobin 
125 Metolachlor-ESA 329.1292 Positive 6.64 1 12.3 10 298.1107 C14H20O4NS Carbamazepine 
126 Metoprolol 267.1829 Positive 4.5 1 9.75 5 159.0806 C11H11O Metoprolol Acid 
127 Metribuzin 214.0883 Positive 6 1 11.62 5 187.1011 C7H15N4S Carbamazepine 
128 Metsulfuron-methyl 381.0738 Positive 6.1 25 11.59 NA 167.0565 C6H7O2N4 Carbofuran 
129 Molinate 187.1031 Positive 9.55 5 14.98 5 126.0914 C7H12ON Oxybenzone 
130 Morphine 285.1359 Positive 1.56 5 7.06 250 201.0911 C13H13O2 Morphine 
131 N,N-didesmethylvenlafaxine 249.1724 Positive 5.52 1 10.87 5 147.0805 C10H11O Venlafaxine 
132 N4-acetylsulfamethoxazole 295.0622 Positive 4.8 1 10.19 5 198.0221 C8H8O3NS Sulfamethoxazole 
133 Nadolol 309.1935 Positive 3.55 1 9 5 254.1388 C13H20O4N Iopromid 
134 Naproxen 230.0937 Positive 9 1 14.44 10 185.0963 C13H13O Naproxen 
135 Nicotine 162.1157 Positive 1.11 5 6.23 NA 102.9704 C6H3N2 Metformin 
136 Norfloxacin 319.1327 Positive 3.7 5 9.2 NA 276.1507 C15H19ON3F Thiabendazole 
137 Ofloxacin 361.1433 Positive 3.53 5 9.02 NA 318.1613 C17H21O2N3F Thiabendazole 
138 Oxazepam 286.0504 Positive 7.8 5 13.3 50 241.0528 C14H10N2Cl Isoproturon 
139 Oxcarbazepine 252.0899 Positive 5.7 1 11.18 5 208.0749 C14H10ON Carbamazepine 
140 Oxybenzone 228.0786 Positive 10.95 1 16.33 5 151.0391 C8H7O3 Oxybenzone 
141 Paraxanthine 180.0647 Positive 2.8 5 8.4 50 124.0507 C5H6ON3 Acetaminophen 
142 Penciclovir 253.1170 Positive 1.32 25 6.78 2000 152.0568 C5H6ON5 Allopurinol 
143 Pentoxyfylline 278.1379 Positive 4.7 1 10.12 5 181.0722 C7H9O2N4 Carbofuran 
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144 Perfluoroctanoic acid  
(PFOA) 413.9743 Negative 11.2 1 17 5 218.9857 C4F9 Triclosan 
145 Phenobarbital 232.0848 Negative 5.25 5 10.82 100 160.0843 C6H12O3N2 Sucralose 
146 Phenytoin (Dilantin) 252.0899 Positive 6.5 5 11.95 10 182.0966 C13H12N Carbofuran 
147 Pirimicarb 238.1430 Positive 4.1 1 9.69 1 182.1289 C9H16ON3 Pirimicarb 
148 Pirimiphos-Ethyl 333.1271 Positive 12.9 1 18.54 5 198.1062 C9H16N3S Efavirenz 
149 Primidone 218.1050 Positive 4.6 5 10.3 10 162.0915 C10H12ON Erythromycin 
150 Progesterone 314.2246 Positive 11.6 5 16.92 10 297.2211 C21H29O3 Efavirenz 
151 Prohexadione Ca 462.0833 Negative 5.45 5 11.07 10 111.0438 C6H7O2 Sucralose 
152 Prometon 225.1584 Positive 5.8 1 11.2 0.1 142.0725 C4H8ON5 Carbaryl 
153 Propachlor 211.0758 Positive 7.5 1 13 0.5 170.0368 C8H9ONCl Fexofenadine 
154 Propachlor ESA 257.0716 Negative 4.7 5 10.43 25 162.0220 C5H8O3NS Mecoprop 
155 Propachlor OXA 207.0890 Positive 4.8 5 10.54 10 120.0444 C7H6ON Carbofuran 
156 Propazine 229.1089 Positive 8.64 1 14.18 0.5 146.0229 C3H5N5Cl Azoxystrobin 
157 Propoxur 209.1047 Positive 6 25 11.55 5 111.0441 C6H7O2 Carbaryl 
158 Propranolol HCl 259.1572 Positive 6.16 1 11.15 5 183.0806 C13H11O Erythromycin 
159 Propyzamide 255.0218 Positive 9.6 1 15.08 5 172.9557 C7H3OCl2 Isoproturon 
160 Pseudoephedrine 165.2345 Positive 2.8 1 8.35 50 133.0887 C9H11N Iopromid 
161 Pyrazophos 373.0856 Positive 12.1 1 17.61 10 222.0875 C10H12O3N3 Ibuprofen_Na 
162 Ranitidine HCl 314.1407 Positive 2.2 5 7.74 250 176.0490 C5H10O2N3S Ranitidine 
163 Ritalinic Acid 219.1254 Positive 4.05 1 9.6 5 174.1278 C12H16N Imidacloprid 
164 Serotonin HCl 176.0944 Positive 1.75 5 7.16 750 146.0602 C9H8ON Morphine 
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165 Siduron 232.1576 Positive 8.9 5 14.39 5 137.0711 C7H9ON2 Celecoxib 
166 Simazine 201.0776 Positive 6 1 11.56 5 132.0324 C4H7N3Cl Atrazine 
167 Sitagliptin 407.1181 Positive 4.55 5 9.98 5 235.0802 C8H10ON4F3 Erythromycin 
168 Sucralose 396.0146 Negative 3.9 5 9.5 100 278.1482 C11H18O8 Sucralose 
169 Sulfadimethoxine 310.0730 Positive 4.9 1 10.41 5 237.0401 C12H5O2N4 Sulfadimethoxine 
170 Sulfamethazine 278.0832 Positive 3.27 5 8.91 10 204.0440 C12H4N4 Caffeine 
171 Sulfamethoxazole 253.0516 Positive 3.9 1 9.56 10 156.0114 C6H6O2NS Sulfamethoxazole 
172 Sulfathiazole 255.0131 Positive 2.6 25 8.16 250 156.0114 C6H6O2NS Sulfadimethoxine 
173 TDCPP 427.8834 Positive 11.9 1 17.34 100 98.9843 CH4O3Cl Tris (2-chloro-ethyl) phosphate 
174 Temazepam 300.0660 Positive 8.1 1 13.59 25 255.0684 C15H12N2Cl Isoproturon 
175 Terbutylazine 229.1089 Positive 9 1 14.46 0.5 174.0543 C5H9N5Cl Celecoxib 
176 Testosterone 288.2089 Positive 9.6 1 14.95 10 253.1953 C19H25 Isoproturon 
177 Theophylline 180.0647 Positive 2.92 5 8.4 50 124.0507 C5H6ON3 Imidacloprid 
178 Thiabendazole 201.0355 Positive 3.45 1 9.11 5 175.0326 C9H7N2S Thiabendazole 
179 Tramadol 263.1885 Positive 4.2 1 9.7 10 201.1278 C14H17O Sulfamethoxazole 
180 Triamterene 253.1076 Positive 4 1 9.49 5 237.0884 C9H8ON5Cl Imidacloprid 
181 Tributyl phosphate  
(TBP) 266.1647 Positive 13.1 1 18.5 10 155.0468 C4H12O4P Gemfibrozil 
182 Triclosan 287.9506 Negative 13.5 50 18.96 50 165.8927 C5HCl3 Triclosan 
183 Trimethoprim 290.1373 Positive 3.4 1 8.83 5 245.1035 C12H13O2N4 Trimethoprim 
184 Trinexapac-ethyl 252.0992 Positive 7.9 1 13.33 5 183.0290 C8H7O5 Isoproturon 
185 Tris (2-chloro-ethyl) 
phosphate (TCEP) 283.9539 Positive 6.3 5 11.8 5 160.9766 C2H7O4ClP 
Tris (2-chloro-ethyl) 
phosphate 
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186 Valsartan 435.2270 Positive 9.7 1 15.19 10 235.0985 C14H11N4 Isoproturon 
187 Venlafaxine HCl 277.2036 Positive 5.5 1 10.76 10 215.1431 15H19O Venlafaxine 
188 Verapamil HCl 454.2832 Positive 6.4 1 11.67 50 303.2066 C18H27O2N2 Citalopram 
189 Warfarin 308.1043 Positive 9.5 1 14.86 5 251.0705 C16H11O3 Fexofenadine 
a. The major ionization mode of compounds after electrospray ionization (ESI); 
b. “RT” stands for retention time, unit in minutes; 
c. Units in ng L-1; “NA” stands for Not Available; reported LODs are direct inject concentration; 
d. “Fragment” means most intense fragment used for LOD determination. 
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Appendix C - Experimental Data for Targeted Compounds 
Table C1. Base case absolute recovery rates obtained using HLB and P-CDP. 
No.a 180 mg HLB AbsRec (%)b 
Measured HLB Min 
AbsRec (%) 
Measured HLB 
Max AbsRec (%) 
Reported HLB 
AbsRec (%)c 
180mg P-CDP 
AbsRec (%)b 
Measured P-CDP 
Min AbsRec (%) 
Measured P-CDP Max 
AbsRec (%) 
1 117.0 115.1 118.1 109 53.4 52.7 53.9 
2 58.8 57.4 61.3 58 0.1 0.0 0.2 
3 69.1 68.8 69.4  5.1 4.8 5.3 
4 13.4 10.2 18.1  90.9 82.5 98.7 
5 1.8 1.6 2.0 25 1.3 0.8 1.6 
6 81.1 76.5 89.2 90 1.0 0.8 1.2 
7 94.3 91.7 98.5 93 24.4 23.0 25.7 
8 111.4 106.6 119.7  122.5 116.1 130.0 
9 104.8 101.5 108.7  95.2 85.4 100.9 
10 79.2 75.2 85.7  14.3 12.4 17.7 
11 90.2 84.8 95.0  1.0 0.7 1.4 
12 80.4 74.1 86.3  0.1 0.0 0.1 
13 3.7 2.9 4.1  0.4 0.2 0.5 
14 1.1 1.0 1.1  0.0 0.0 0.0 
15 24.7 23.8 26.0  32.1 30.9 33.1 
16 98.4 95.1 101.9 97 81.7 78.9 85.8 
17 39.8 37.7 41.9 24 36.7 34.8 39.4 
18 107.5 104.9 109.4 89 13.9 9.0 19.9 
19 0.1 0.0 0.2  0.0 0.0 0.0 
20 94.0 91.8 97.7  83.6 77.3 87.2 
21 107.5 104.9 109.4 89 13.9 9.0 19.9 
22 24.7 24.0 26.1 14 0.2 0.1 0.2 
23 60.1 55.7 67.8  98.1 86.8 111.7 
24 70.4 68.4 73.1 85 0.0 0.0 0.0 
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25 19.4 14.3 23.7 83 0.1 0.0 0.1 
26 75.6 72.6 78.5 26 0.0 0.0 0.0 
27 31.2 20.4 38.5  2.0 0.0 3.2 
28 2.8 2.5 3.2  0.0 0.0 0.0 
29 49.0 48.1 49.7 35 0.0 0.0 0.0 
30 14.6 14.2 15.1 4 1.7 1.2 2.5 
31 9.1 6.9 11.7 75 0.1 0.0 0.1 
32 74.5 72.5 77.5 93 7.6 5.4 10.9 
33 106.4 98.4 111.8 93 44.5 43.6 46.2 
34 96.4 94.1 98.2 98 84.8 80.9 88.3 
35 1.6 1.5 1.7 93 3.5 2.4 5.0 
36 66.7 65.4 69.1  0.0 0.0 0.0 
37 96.9 89.3 102.6 91 90.2 89.8 90.7 
38 10.7 10.4 11.1  2.8 2.3 3.7 
39 102.3 99.8 106.3  61.1 58.4 63.8 
40 126.7 125.2 127.5 96 0.1 0.1 0.1 
41 96.4 95.6 97.2 87 72.5 66.0 76.3 
42 80.8 75.6 85.5 88 34.0 32.9 35.7 
43 7.5 7.2 7.7 50 13.2 11.1 15.2 
44 93.5 91.8 94.9 93 19.7 19.1 20.2 
45 0.9 0.0 2.8  0.5 0.0 1.4 
46 106.3 101.6 111.9 91 85.8 70.6 96.7 
47 99.3 97.0 101.1  26.2 25.4 26.9 
48 101.4 87.1 110.2 96 2.4 1.6 3.0 
49 95.8 94.8 97.2 97 72.6 70.1 76.3 
50 88.1 85.9 89.6 99 66.0 63.7 70.0 
51 94.0 91.5 95.6 91 45.2 45.0 45.4 
52 82.3 80.0 85.5  67.5 65.4 69.7 
53 98.5 80.6 108.3  92.8 89.2 95.7 
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54 94.5 91.0 99.5 95 76.6 72.0 82.3 
55 48.4 46.1 51.5  0.1 0.1 0.2 
56 8.2 5.1 12.0 77 0.0 0.0 0.0 
57 94.0 88.3 97.1 85 0.1 0.0 0.2 
58 51.5 41.4 60.7 86 0.0 0.0 0.1 
59 62.3 52.0 77.3 84 0.7 0.0 1.8 
60 86.8 81.8 93.9 95 128.0 123.7 132.8 
61 79.9 75.6 82.9 98 0.6 0.4 0.8 
62 61.7 55.1 74.3 87 0.0 0.0 0.0 
63 99.9 96.0 105.7  65.0 57.2 79.8 
64 41.1 35.5 48.2  15.4 14.0 16.8 
65 80.7 73.3 89.3  54.9 49.5 60.3 
66 111.3 103.1 115.8  126.0 125.4 127.2 
67 21.4 7.9 34.9  125.2 120.7 129.8 
68 9.5 9.1 9.8 100 11.1 8.6 14.0 
69 117.7 103.6 134.9  73.5 65.3 81.1 
70 63.7 61.7 65.3 79 0.0 0.0 0.0 
71 91.0 87.2 95.2 92 67.1 65.6 68.2 
72 96.5 86.7 102.6 79 0.0 0.0 0.0 
73 97.0 94.1 102.0 93 19.8 14.7 23.9 
74 121.3 111.2 127.7  127.2 122.5 130.8 
75 104.1 101.4 107.6 95 65.1 56.0 70.3 
76 97.1 95.4 100.3 93 63.3 61.0 65.3 
77 119.3 111.4 127.1 88 0.0 0.0 0.0 
78 96.5 93.0 98.8 97 99.7 94.9 105.3 
79 92.0 86.9 95.6  98.2 95.3 104.0 
80 90.3 87.6 95.1  45.5 43.4 49.3 
81 96.0 86.1 101.3 90 71.3 65.0 81.5 
82 95.2 88.2 102.4  69.7 66.9 75.0 
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83 105.7 100.6 111.6  75.9 68.9 87.0 
84 73.3 65.5 78.8  0.0 0.0 0.0 
85 87.1 85.7 87.9 90 1.0 0.7 1.5 
86 101.4 96.6 106.2 93 20.8 19.8 21.5 
87 85.3 80.1 88.1 71 0.1 0.0 0.3 
88 16.3 15.4 17.2  0.0 0.0 0.0 
89 96.6 91.0 101.0 87 33.2 24.9 43.6 
90 1.3 1.2 1.4 1 1.6 1.3 1.8 
91 90.8 88.0 93.6  57.2 51.6 63.4 
92 12.7 11.5 13.8  0.1 0.1 0.2 
93 79.7 72.9 86.3  1.0 1.0 1.1 
94 95.1 93.2 97.2 90 73.0 69.3 77.8 
95 95.1 90.6 103.8 97 79.2 70.9 83.5 
96 84.3 74.7 102.8  0.0 0.0 0.0 
97 104.2 101.0 110.0  53.0 48.4 57.9 
98 94.2 91.0 98.0 102 13.1 9.0 16.3 
99 93.9 90.8 96.7 98 73.9 71.2 75.4 
100 80.8 71.5 91.0 94 89.1 80.6 93.9 
101 101.0 94.4 106.7 88 0.0 0.0 0.0 
102 98.4 88.3 104.1 98 28.1 27.5 29.0 
103 99.4 95.3 103.2 93 124.3 120.0 128.9 
104 123.4 119.1 127.2 97 68.6 62.9 73.0 
105 92.0 89.6 93.4 91 97.6 95.6 100.2 
106 62.8 62.5 63.4 101 0.1 0.1 0.1 
107 124.2 121.9 126.2 96 21.7 15.2 25.8 
108 103.5 101.9 106.5 92 2.3 1.7 3.1 
109 9.6 9.0 10.0 5 0.7 0.7 0.8 
110 82.9 75.8 88.8 93 0.3 0.3 0.3 
111 98.3 94.7 102.7 98 114.6 101.4 127.2 
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112 123.9 122.0 125.0 75 82.4 70.3 91.8 
113 62.8 57.4 72.4  0.1 0.0 0.2 
114 82.3 75.0 92.2 97 1.3 0.9 1.6 
115 91.3 90.7 92.0  0.7 0.4 0.9 
116 99.6 92.3 105.3  57.9 51.1 68.5 
117 100.1 96.4 105.8 92 49.1 44.0 52.3 
118 97.3 89.1 103.4 93 63.5 60.4 68.2 
119 98.7 95.5 100.9  96.5 91.0 104.9 
120 0.0 0.0 0.1  0.0 0.0 0.0 
121 2.4 0.4 3.6 88 0.0 0.0 0.0 
122 98.9 92.5 105.8 89 112.9 99.7 126.3 
123 83.9 76.8 87.6 66 32.4 29.6 37.6 
124 106.2 103.0 108.3 94 69.3 64.5 76.5 
125 96.5 92.8 99.4 99 0.0 0.0 0.0 
126 67.6 63.9 73.1 90 0.0 0.0 0.0 
127 119.2 112.1 127.0 90 91.2 86.0 94.1 
128 106.0 101.8 112.4 91 0.0 0.0 0.0 
129 115.4 104.4 121.4  40.6 34.5 48.5 
130 65.2 62.6 67.4 77 0.0 0.0 0.0 
131 73.9 60.5 83.4 27 0.0 0.0 0.0 
132 80.9 76.7 85.2 97 10.6 8.1 13.3 
133 94.7 86.8 99.4  0.0 0.0 0.0 
134 102.6 98.2 110.4 91 36.5 29.0 44.7 
135 9.4 6.3 13.4  0.0 0.0 0.0 
136 9.9 6.4 13.1 78 0.0 0.0 0.0 
137 20.7 12.4 31.2  0.0 0.0 0.0 
138 96.0 93.8 97.1 92 70.4 69.1 71.2 
139 128.9 127.0 129.9 79 83.2 79.8 87.3 
140 110.5 95.4 118.4 84 54.2 49.6 62.7 
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141 52.0 49.9 55.1  18.1 16.6 18.9 
142 3.6 3.3 3.9  6.1 5.5 6.5 
143 90.1 89.3 90.6  55.9 54.1 59.0 
144 10.4 8.7 13.4  0.6 0.3 0.9 
145 101.9 97.0 107.8  30.4 27.4 36.0 
146 84.9 83.2 86.4  62.1 56.5 65.0 
147 94.8 91.7 99.5 95 87.4 86.0 89.9 
148 19.1 16.3 24.4  48.3 44.0 53.0 
149 110.2 103.5 117.0 96 32.6 25.2 37.5 
150 130.5 127.3 132.9  111.4 102.7 119.5 
151 49.7 45.4 53.2  0.3 0.2 0.3 
152 91.5 89.1 94.4 90 68.6 66.8 70.1 
153 9.4 9.2 9.6 97 11.6 9.4 14.4 
154 30.3 26.0 32.7 31 0.0 0.0 0.0 
155 4.4 4.3 4.6 4 0.0 0.0 0.0 
156 94.9 92.3 96.9 90 58.2 47.4 66.0 
157 109.5 106.0 112.3  56.3 51.2 62.4 
158 48.3 46.6 51.6 97 0.1 0.0 0.1 
159 105.0 96.9 109.8  99.6 98.3 100.7 
160 78.4 75.7 82.3  0.1 0.0 0.1 
161 17.3 9.7 26.5  76.8 70.3 81.3 
162 72.2 71.5 73.3 55 0.0 0.0 0.0 
163 32.6 32.3 33.0 17 2.6 2.4 2.8 
164 35.7 32.0 37.6  2.3 0.0 6.8 
165 116.6 108.4 127.1  14.6 10.5 20.3 
166 96.1 85.3 106.0 93 95.0 89.9 98.1 
167 111.1 109.1 114.3 45 0.0 0.0 0.0 
168 84.1 82.9 85.6 75 0.8 0.6 1.1 
169 93.3 90.0 97.2 99 70.1 65.7 77.6 
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170 128.0 122.0 137.3 94 79.2 77.4 81.3 
171 98.4 95.3 101.6 97 34.6 29.0 39.9 
172 94.0 84.7 99.3 101 36.4 29.8 42.3 
173 104.5 101.5 109.1  122.7 119.4 124.8 
174 109.4 106.9 112.9  86.8 81.4 91.8 
175 114.3 104.3 124.2 100 14.0 9.8 19.9 
176 103.2 101.0 106.0  117.9 112.6 122.9 
177 50.0 46.8 52.2  14.3 12.9 16.4 
178 94.2 89.9 96.6  27.4 23.9 33.5 
179 63.7 61.7 65.3 100 0.0 0.0 0.0 
180 57.5 53.3 65.5  0.0 0.0 0.0 
181 26.9 25.1 28.0  18.3 16.5 20.0 
182 63.2 60.8 65.8 89 72.5 71.5 73.8 
183 75.6 64.2 97.3 99 0.6 0.0 1.6 
184 122.3 112.4 133.1 98 16.2 14.1 19.0 
185 93.8 90.0 96.9  61.2 58.6 65.3 
186 125.8 119.4 132.2 91 1.5 0.5 2.0 
187 98.9 96.4 101.1 92 0.0 0.0 0.0 
188 0.4 0.0 1.1 87 0.4 0.2 0.8 
189 12.3 11.5 13.0  12.0 10.5 13.1 
a. No. refers each targeted compound in Table B; 
b. all SD value in this table were calculated from three replicates; value in red means SD is greater than 10%; 
c. all data reported are obtained from the previous study with 200 mg HLB as adsorbent (Vogler, 2013); value in blue means the difference between reported data and measure 
data is above 20
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Table C2. Base case absolute capture rates obtained using HLB and P-CDP. 
Compound Name HLB
a 
AbsCap (%) 
HLBb 
R/C Ratio 
P-CDPa 
AbsCap (%) 
P-CDPb 
R/C Ratio 
10,11-dihydrocarbamazepine 93.4 ± 9.8 1.25 65.7 ± 10.7 0.81 
2-aminobenzimidazole 95 ± 7.9 0.62 99.7 ± 0.6 0.00 
2-mercaptobenzothiazole 100 ± 0 0.13 98.2 ± 2.8 0.93 
2,4-D 96.4 ± 5 0.84 18.5 ± 8.3 0.05 
6-benzylaminopurine 100 ± 0 1.05 99.4 ± 0.6 0.96 
Abacavir 94.9 ± 7.5 0.83 99.7 ± 0.3 0.14 
Abscisic Acid 85.3 ± 8.5 1.06 9.4 ± 7.1 0.11 
Acebutolol HCl 100 ± 0 0.80 100 ± 0 0.00 
Acetamiprid 99.8 ± 0.6 0.99 87.9 ± 7.6 0.93 
Acetochlor 100 ± 0 1.29 90.6 ± 5.3 0.15 
Adrenosterone 97 ± 5.1 0.97 94.6 ± 3.9 0.88 
Alachlor 100 ± 0 1.29 90.6 ± 5.3 0.15 
Albuterol 19.6 ± 6.4 1.26 100 ± 0 0.00 
Amicinonide 96.3 ± 9.2 0.62 99.8 ± 0.5 0.98 
Amisulpride 100 ± 0 0.70 100 ± 0 0.00 
Amitriptyline HCl 100 ± 0 0.19 100 ± 0 0.00 
Amphetamine 89.8 ± 8.9 0.84 100 ± 0 0.00 
Ampicillin 41.1 ± 13.3 0.76 11.3 ± 8.4 0.18 
Atenolol 80 ± 14.5 0.61 100 ± 0 0.00 
Atenolol Acid 23.9 ± 7.3 0.61 85.3 ± 7 0.02 
Atomexine HCl 100 ± 0 0.09 100 ± 0 0.00 
Atrazin-2-Hydroxy 95.5 ± 7.5 0.78 99.8 ± 0.3 0.08 
Atrazin-desethyl 95.2 ± 9.6 1.12 48.6 ± 6.1 0.92 
Atrazine 98 ± 3.4 0.98 78.8 ± 6.2 1.08 
Atropine 100 ± 0 0.67 100 ± 0 0.00 
Azoxystrobin 95.2 ± 6.6 1.02 99.4 ± 0.5 0.91 
Baclofen 11.6 ± 5.5 0.93 14.6 ± 6.5 0.19 
Bendiocarb 100 ± 0 1.02 67.1 ± 6.3 0.91 
Bentazon 88.5 ± 6.4 1.36 33.6 ± 13.5 0.00 
Benzisothiazolin-3-on (BIT) 94.4 ± 7.4 1.02 77.3 ± 8 0.94 
Benzotriazole 83.3 ± 14.5 0.97 66.5 ± 17 0.51 
Benzotriazole-methyl-1H 95.3 ± 6.4 0.08 92.9 ± 4.5 0.14 
Benzoylecgonine 84.1 ± 11.8 1.11 24.4 ± 4 0.81 
Bromacil 92.2 ± 5.1 1.32 63 ± 6.5 2.00 
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Caffeine 95 ± 6.1 1.05 51.8 ± 14.8 0.51 
Candesartan 100 ± 0 1.20 3.5 ± 2.8 0.68 
Carbamazepine 90.4 ± 10.6 1.06 73 ± 8.2 1.00 
Carbendazim 82.2 ± 6.4 1.07 98.7 ± 0.6 0.67 
Carbofuran 100 ± 0 0.94 52.2 ± 8.1 0.87 
Carisoprodol 89.9 ± 5.9 0.91 63 ± 8.2 1.07 
Celecoxib 100 ± 0 0.99 8.1 ± 3.2 11.45 
Chloridazon 100 ± 0 0.94 90.6 ± 6.6 0.84 
Cimetidine 100 ± 0 0.48 100 ± 0 0.00 
cis-diltiazem 100 ± 0 0.94 100 ± 0 0.00 
Citalopram HBr 100 ± 0 0.52 100 ± 0 0.00 
Clarithromycin 100 ± 0 0.62 99.6 ± 1.2 0.01 
Climbazole 98.1 ± 3.4 0.89 99.9 ± 0.2 1.28 
Clofibric Acid 94.9 ± 6.1 0.84 4.5 ± 3.5 0.14 
Codeine 100 ± 0 0.62 100 ± 0 0.00 
Corticosterone 99.7 ± 0.6 1.00 92.8 ± 4.6 0.70 
Coumarin 96.7 ± 3.7 0.84 93.1 ± 4.4 0.59 
Cyanazine 100 ± 0 1.23 87.5 ± 9.9 1.44 
Cyflufenamid 100 ± 0 0.21 99.8 ± 0.3 1.22 
DEET 96.1 ± 5.5 0.10 62.5 ± 11.8 0.18 
Dehydroacetic Acid 96.8 ± 6.2 1.30 13.3 ± 8.9 5.54 
Desvenlafaxine 100 ± 0 0.64 100 ± 0 0.00 
Dexamethasone 100 ± 0 0.91 84.9 ± 8.3 0.79 
Dextromethorphan HBr 100 ± 0 0.96 100 ± 0 0.00 
Diclofenac 100 ± 0 0.97 7.5 ± 3.3 2.63 
Diethyl Phthalate 79 ± 10.5 1.54 79.5 ± 10.9 1.60 
Dimethachlor 100 ± 0 1.04 67.4 ± 7.2 0.97 
Dimethoate 98.4 ± 4 0.99 64.7 ± 10.7 0.98 
Diphenhydramine HCl 100 ± 0 0.97 100 ± 0 0.00 
Diuron 97.4 ± 4.7 0.99 99.9 ± 0.1 1.00 
Efavirenz 98.9 ± 2.6 0.93 99.6 ± 0.4 0.99 
Estrone 100 ± 0 0.90 100 ± 0 0.46 
Ethofumesate 98.9 ± 2.7 0.97 99.8 ± 0.5 0.71 
Famciclovir 86.6 ± 13.8 1.22 96.5 ± 2.4 0.79 
Famotidine 100 ± 0 0.73 100 ± 0 0.00 
Fexofenadine HCl 100 ± 0 0.87 100 ± 0 0.01 
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Fluconazole 93.3 ± 6.4 1.09 16.1 ± 7.6 1.29 
Fluoxetine HCl 100 ± 0 0.85 100 ± 0 0.00 
Folic Acid 18.4 ± 8.1 0.89 4.8 ± 3.2 0.00 
Furosemide 96 ± 9.7 0.96 4.1 ± 4.9 8.07 
Gabapentin 13.8 ± 2.7 0.10 1.8 ± 2.1 0.88 
Gemfibrozil 98.6 ± 1.8 0.92 60.3 ± 9.2 0.95 
Gibberellic Acid 100 ± 0 0.13 5.4 ± 6.1 0.03 
Hexamethylphosphoramide 58.7 ± 8.4 1.36 6 ± 5.8 0.17 
Hexazinone 90.5 ± 6.4 1.05 78.6 ± 9.6 0.93 
Hydrocodone 100 ± 0 0.84 100 ± 0 0.00 
Hydrocortisone 99.7 ± 0.5 1.04 75.7 ± 7.1 0.70 
Ibuprofen 94.3 ± 7.9 1.00 23.3 ± 7.2 0.56 
Imidacloprid 90.5 ± 3.3 1.04 86.1 ± 7.5 0.86 
Ioxynil 97.2 ± 6 1.01 12.5 ± 8.9 2.24 
Irbesartan 93.4 ± 6.1 1.07 68 ± 11.2 1.83 
Isophorone Diisocyanate 92.6 ± 4.3 1.27 60.6 ± 6.2 1.90 
Isoproturon 91.1 ± 6.6 1.01 98.3 ± 1.1 0.99 
Ketamine HCl 99.5 ± 1.1 0.63 100 ± 0 0.00 
Ketoprofen 100 ± 0 1.24 3.1 ± 5.1 7.00 
Lamotrigine 100 ± 0 1.03 100 ± 0 0.02 
Lidocaine 100 ± 0 0.83 100 ± 0 0.00 
Linuron 94.1 ± 6.2 1.04 99.9 ± 0.1 1.15 
Losartan Potassium 99.3 ± 1.7 1.25 26.8 ± 7.3 3.07 
Mabuterol HCl 100 ± 0 0.63 100 ± 0 0.00 
MCPA 98.2 ± 3.5 0.84 25.7 ± 10.4 0.05 
Mecoprop 91.6 ± 9.9 1.00 5.3 ± 6.3 0.13 
Meprobamate 100 ± 0 1.30 29.7 ± 9.3 1.50 
Metalaxyl 91.2 ± 5.9 1.10 58 ± 12.7 0.85 
Metamitron 92.8 ± 7.7 1.05 95.1 ± 4 0.67 
Metaxalone 90.2 ± 5.3 1.09 96.9 ± 2.3 1.00 
Methadone 100 ± 0 0.20 100 ± 0 0.00 
Methocarbamol 100 ± 0 1.19 74.6 ± 8.4 1.74 
Metolachlor 100 ± 0 1.06 87.2 ± 6.4 0.79 
Metolachlor-ESA 89.3 ± 8.9 1.08 15.6 ± 6.4 0.00 
Metoprolol 100 ± 0 0.68 100 ± 0 0.00 
Metribuzin 100 ± 0 1.19 75.4 ± 8.7 1.21 
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Molinate 100 ± 0 0.96 91.5 ± 5.9 0.44 
N,N-didesmethylvenlafaxine 100 ± 0 0.74 100 ± 0 0.00 
N4-acetylsulfamethoxazole 100 ± 0 0.81 29.7 ± 9.6 0.36 
Nadolol 100 ± 0 0.95 100 ± 0 0.00 
Naproxen 99.8 ± 0.4 1.03 50.3 ± 6.3 0.73 
Oxazepam 81.8 ± 13.5 1.17 74.9 ± 8.9 0.94 
Oxcarbazepine 96.5 ± 3.6 0.86 64.5 ± 11 1.29 
Oxybenzone 95.7 ± 5 0.84 99.8 ± 0.8 0.54 
Paraxanthine 39.2 ± 8.6 1.33 13.4 ± 7.3 1.20 
Pentoxyfylline 84.1 ± 7 1.07 86.7 ± 8.4 0.64 
Perfluoroctanoic acid (PFOA) 91.9 ± 8.2 0.11 0 ± 0 0.00 
Phenobarbital 86.2 ± 8.2 1.18 43.4 ± 9.9 0.70 
Phenytoin (Dilantin) 91.2 ± 1.5 0.93 74.8 ± 5.2 0.83 
Pirimicarb 99.1 ± 1.7 0.96 96.6 ± 3 0.90 
Pirimiphos-Ethyl 100 ± 0 0.19 100 ± 0 0.48 
Primidone 100 ± 0 1.03 22 ± 10.3 2.05 
Progesterone 97.5 ± 6.4 1.34 99.9 ± 0.1 1.12 
Prohexadione Ca 39.1 ± 8.9 1.27 0.8 ± 0.2 0.35 
Prometon 94.1 ± 6.7 0.97 96.4 ± 2.1 0.71 
Propachlor 100 ± 0 0.09 66.4 ± 7.8 0.17 
Propachlor ESA 80.7 ± 11.3 0.38 7.5 ± 5.9 0.00 
Propachlor OXA 83.7 ± 2.8 0.05 5.3 ± 3.4 0.00 
Propazine 98.9 ± 1.9 0.96 98.5 ± 4.2 0.59 
Propoxur 100 ± 0 1.09 65.2 ± 11.3 0.86 
Propranolol HCl 100 ± 0 0.49 100 ± 0 0.00 
Propyzamide 100 ± 0 1.05 95.7 ± 2.8 1.04 
Pseudoephedrine 58.9 ± 10.6 0.67 100 ± 0 0.00 
Pyrazophos 98.3 ± 3 0.28 100 ± 0 0.77 
Ritalinic Acid 27.9 ± 4.3 1.17 0.7 ± 1.1 3.94 
Siduron 89.2 ± 9.5 1.31 97.5 ± 1.6 0.15 
Simazine 99.9 ± 0.2 0.96 75.2 ± 7.2 1.26 
Sitagliptin 100 ± 0 1.13 100 ± 0 0.00 
Sucralose 84.1 ± 9.3 1.00 1.1 ± 2.5 0.76 
Sulfadimethoxine 98.9 ± 2.6 0.94 70.7 ± 8.7 0.99 
Sulfamethazine 100 ± 0 1.28 34.5 ± 9.7 2.29 
Sulfamethoxazole 100 ± 0 0.98 25 ± 9.4 1.38 
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TDCPP 89.6 ± 8.3 1.17 98.6 ± 2.5 1.24 
Temazepam 99.5 ± 1.1 1.10 84.9 ± 8.4 1.02 
Terbutylazine 100 ± 0 1.19 98.5 ± 4.2 0.14 
Testosterone 88.4 ± 12.4 1.17 98.1 ± 1.5 1.20 
Theophylline 35.7 ± 10.6 1.40 13.4 ± 7.3 1.07 
Thiabendazole 96.7 ± 6.5 0.97 100 ± 0 0.27 
Tramadol 100 ± 0 0.64 100 ± 0 0.00 
Triamterene 100 ± 0 0.57 100 ± 0 0.00 
Tributyl phosphate (TBP) 84.8 ± 8.9 0.32 94.1 ± 5.2 0.19 
Triclosan 83.3 ± 4.8 0.76 98.3 ± 3.2 0.74 
Trimethoprim 99.8 ± 0.4 0.76 99.9 ± 0.3 0.01 
Trinexapac-ethyl 98.3 ± 4.1 1.24 17.8 ± 6 0.91 
Tris (2-chloro-ethyl) phosphate (TCEP) 95.4 ± 6.6 0.98 68.2 ± 7.1 0.90 
Valsartan 100 ± 0 1.23 0.3 ± 0.6 4.99 
Venlafaxine HCl 100 ± 0 0.99 100 ± 0 0.00 
Verapamil HCl 100 ± 0 0.00 100 ± 0 0.00 
Warfarin 97.7 ± 5.6 0.13 43 ± 8.7 0.28 
a. all SD data were standard deviations calculated from nine data points from three replicates; 
b. R/C ratios were calculated using Equation (3); 
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Table C3. Improved absolute capture rates obtained using P-CDP. 
Compound Name pH 6 / 500 mg b pH 3 / 500 mg b 
10,11-dihydrocarbamazepine 100 ± 0 100 ± 0 
2-aminobenzimidazole 100 ± 0 100 ± 0.1 
2-mercaptobenzothiazole 100 ± 0 79.8 ± 12.4 
2,4-D 15.5 ± 9.6 100 ± 0 
6-benzylaminopurine 100 ± 0 100 ± 0 
Abacavir 100 ± 0 100 ± 0 
Abscisic Acid 11.9 ± 8 100 ± 0 
Acebutolol HCl 100 ± 0 100 ± 0 
Acetamiprid 100 ± 0 99.9 ± 0.2 
Acetochlor 100 ± 0 100 ± 0 
Adrenosterone 100 ± 0 100 ± 0 
Alachlor 100 ± 0 100 ± 0 
Albuterol Sulfate 100 ± 0 100 ± 0 
Amicinonide 100 ± 0 100 ± 0 
Amisulpride 100 ± 0 100 ± 0 
Amitriptyline HCl 100 ± 0 100 ± 0 
Amphetamine 100 ± 0 100 ± 0 
Ampicillin 35.2 ± 12.2 94.2 ± 6 
Atenolol 100 ± 0 100 ± 0 
Atenolol Acid 100 ± 0 100 ± 0 
Atomexine HCl 100 ± 0 100 ± 0 
Atrazin-2-Hydroxy 100 ± 0 100 ± 0 
Atrazin-desethyl 99.1 ± 2.2 98.9 ± 2.3 
Atrazine 100 ± 0 100 ± 0.1 
Atropine 99.9 ± 0 99.9 ± 0.2 
Azoxystrobin 82.3 ± 6.6 100 ± 0 
Baclofen 100 ± 0 100 ± 0 
Bendiocarb 100 ± 0 100 ± 0 
Bentazon 72.6 ± 8.6 100 ± 0 
Benzisothiazolin-3-on (BIT) 100 ± 0 95.2 ± 5.1 
Benzotriazole 99.5 ± 1.2 100 ± 0 
Benzotriazole-methyl-1H 99.8 ± 0.3 100 ± 0 
Benzoylecgonine 100 ± 0 100 ± 0 
Bromacil 99.5 ± 1.2 100 ± 0 
Caffeine 65.8 ± 16.2 95.4 ± 11.5 
Candesartan 15 ± 6.7 100 ± 0 
Carbamazepine 99.1 ± 0.1 99.4 ± 0.9 
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Carbendazim 100 ± 0 100 ± 0 
Carbofuran 100 ± 0 94 ± 6.9 
Carisoprodol 100 ± 0 100 ± 0 
Celecoxib 19.9 ± 8.3 99.8 ± 0.6 
Chloridazon 100 ± 0 100 ± 0 
Cimetidine 100 ± 0 100 ± 0 
cis-diltiazem 100 ± 0 100 ± 0 
cis-Tramadol HCl 100 ± 0 100 ± 0 
Citalopram HBr 100 ± 0 100 ± 0 
Clarithromycin 100 ± 0 100 ± 0 
Climbazole 99.9 ± 0 100 ± 0 
Clofibric Acid 12.4 ± 6.8 100 ± 0 
Codeine 100 ± 0 100 ± 0 
Corticosterone 100 ± 0 100 ± 0 
Coumarin 98.6 ± 1.3 99.8 ± 0.3 
Cyanazine 100 ± 0 100 ± 0 
Cyflufenamid 100 ± 0 100 ± 0 
DEET 86.2 ± 8.9 99.9 ± 0.1 
Dehydroacetic Acid 58.7 ± 13.1 100 ± 0 
Desvenlafaxine 100 ± 0 100 ± 0 
Dexamethasone 99.9 ± 0.2 100 ± 0 
Dextromethorphan HBr 100 ± 0 100 ± 0 
Diclofenac Na 97.6 ± 4.2 100 ± 0 
Diethyl Phthalate 85.6 ± 7.8 77.8 ± 13.2 
Dimethachlor 100 ± 0 100 ± 0 
Dimethoate 100 ± 0 100 ± 0 
Diphenhydramine HCl 100 ± 0 99.8 ± 0.3 
Diuron 100 ± 0 100 ± 0 
Efavirenz 100 ± 0 100 ± 0 
Estrone 100 ± 0 100 ± 0 
Ethofumesate 84.6 ± 6 100 ± 0 
Famciclovir 100 ± 0 100 ± 0 
Famotidine 100 ± 0 100 ± 0 
Fexofenadine HCl 100 ± 0 100 ± 0 
Fluconazole 100 ± 0 90.7 ± 12.9 
Fluoxetine HCl 100 ± 0 100 ± 0 
Folic Acid 1.7 ± 2.8 100 ± 0 
Furosemide 82.9 ± 8.7 100 ± 0 
Gabapentin 31.8 ± 16.2 53.3 ± 15.7 
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Gemfibrozil 94.3 ± 8.3 100 ± 0 
Gibberellic Acid 8.6 ± 7.4 82.7 ± 7.5 
Hexamethylphosphoramide 22.6 ± 7.4 8.5 ± 7.3 
Hexazinone 100 ± 0 100 ± 0 
Hydrocodone 100 ± 0 100 ± 0 
Hydrocortisone 100 ± 0 100 ± 0 
Ibuprofen 92.3 ± 8.9 100 ± 0 
Imidacloprid 100 ± 0 100 ± 0 
Ioxynil 62.1 ± 8.1 100 ± 0 
Irbesartan 100 ± 0 100 ± 0 
Isophorone Diisocyanate 99.5 ± 0.4 86.1 ± 11.9 
Isoproturon 100 ± 0 100 ± 0 
Ketamine HCl 100 ± 0 100 ± 0 
Ketoprofen 65.4 ± 10 100 ± 0 
Lamotrigine 100 ± 0 100 ± 0 
Lidocaine 100 ± 0 100 ± 0 
Linuron 100 ± 0 99.6 ± 0.9 
Losartan Potassium 99.9 ± 0.3 100 ± 0 
Mabuterol HCl 100 ± 0 100 ± 0 
MCPA 12.4 ± 1.4 100 ± 0 
Mecoprop 12 ± 0.7 100 ± 0 
Meprobamate 100 ± 0 77.6 ± 8.3 
Metalaxyl 100 ± 0 100 ± 0 
Metamitron 99.2 ± 0.6 100 ± 0 
Metaxalone 100 ± 0 100 ± 0 
Methadone 100 ± 0 100 ± 0 
Methocarbamol 100 ± 0 100 ± 0 
Metolachlor 99.8 ± 0.2 100 ± 0 
Metolachlor-ESA 17.1 ± 5.4 7.1 ± 9.5 
Metoprolol Tartrate 100 ± 0 100 ± 0 
Metribuzin 100 ± 0 100 ± 0 
Molinate 100 ± 0 100 ± 0 
N,N-didesmethylvenlafaxine 100 ± 0 100 ± 0 
N4-acetylsulfamethoxazole 96.5 ± 6.3 99.7 ± 0.9 
Nadolol 100 ± 0 100 ± 0 
Naproxen 99.3 ± 0.5 100 ± 0 
Oxazepam 99.7 ± 0.1 100 ± 0 
Oxcarbazepine 100 ± 0 100 ± 0 
Oxybenzone 58.8 ± 5.2 100 ± 0 
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Paraxanthine 97.2 ± 3.1 73.5 ± 7.6 
Pentoxyfylline 100 ± 0 100 ± 0 
Perfluorooctanoic acid (PFOA) 14.9 ± 8 96.5 ± 4.9 
Phenobarbital 100 ± 0 100 ± 0 
Phenytoin (Dilantin) 100 ± 0 100 ± 0 
Pirimicarb 100 ± 0 100 ± 0 
Pirimiphos-Ethyl 100 ± 0 100 ± 0 
Primidone 97.9 ± 1.6 89.1 ± 10.2 
Progesterone 99.9 ± 0.1 100 ± 0 
Prohexadione Ca 12.4 ± 3.9 100 ± 0 
Prometon 99.4 ± 0.2 100 ± 0 
Propachlor 99.8 ± 0.2 100 ± 0 
Propachlor ESA Na 9.5 ± 5.4 4.5 ± 4.1 
Propachlor OXA 12.3 ± 5.8 3.6 ± 4.8 
Propazine 100 ± 0 100 ± 0 
Propoxur 99.4 ± 0.7 100 ± 0 
Propranolol HCl 99.3 ± 0.6 99.8 ± 0.4 
Propyzamide 100 ± 0 100 ± 0 
Pseudoephedrine 100 ± 0 95.8 ± 6.9 
Pyrazophos 100 ± 0 100 ± 0 
Ritalinic Acid 41.8 ± 15.2 76.8 ± 12.5 
Siduron 100 ± 0 100 ± 0 
Simazine 98.9 ± 0.2 99.9 ± 0.2 
Sitagliptin 100 ± 0 99.8 ± 0.3 
Sucralose 53.4 ± 15.3 11.4 ± 6.8 
Sulfadimethoxine 99.9 ± 0.1 98.7 ± 2.4 
Sulfamethazine 100 ± 0 100 ± 0 
Sulfamethoxazole 99.7 ± 0.3 100 ± 0 
TDCPP 76 ± 2.9 98.5 ± 3.5 
Temazepam 99.5 ± 0.4 100 ± 0 
Terbutylazine 0 ± 0 100 ± 0 
Testosterone 99.8 ± 0.2 100 ± 0 
Theophylline 94 ± 5.2 73.6 ± 13.8 
Thiabendazole 100 ± 0 100 ± 0 
Triamterene 70 ± 9.4 100 ± 0 
Tributyl phosphate (TBP) 90.4 ± 8.8 100 ± 0.2 
Triclosan 100 ± 0 100 ± 0 
Trimethoprim 95 ± 5.9 99.8 ± 0.3 
Trinexapac-ethyl 82.2 ± 15.1 99.2 ± 1.5 
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Tris (2-chloro-ethyl) phosphate (TCEP) 93.3 ± 9.2 100 ± 0 
Valsartan 0 ± 0 100 ± 0 
Venlafaxine HCl 100 ± 0 100 ± 0 
Verapamil HCl 100 ± 0 100 ± 0 
Warfarin 100 ± 0 100 ± 0 
a. Charge state of each compound at reported pH, estimated using Marvin Desktop; 
b. Standard deviations were calculated from 6 data points (duplicates; sample collected during loading, at 1 hr, 3 hr and 5 
hr). 
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Table C4. Improved absolute recovery rates obtained using P-CDP. 
No. a 10 mL MeOHb 15 mL MeOHb 15 mL MeOH + NaClc R/C Ratiod 
1 102.4 ± 1.3 105.1 ± 2.9 106 ± 3 1.06 
2 0 ± 0 0.1 ± 0.1 98.3 ± 8.2 0.98 
3 15.6 ± 2.5 17.9 ± 0.8 14.4 ± 2.1 NA 
4 0 ± 0 25.1 ± 5.2 40 ± 6.8 0.50 
5 2.1 ± 0.1 2.1 ± 0.1 1.7 ± 0.1 NA 
6 98.7 ± 4.5 106 ± 7.6 115.5 ± 1.7 1.16 
7 74.5 ± 3 77 ± 2 72.3 ± 0.3 NA 
8 12.1 ± 10.6 88.3 ± 2.8 78.6 ± 12.2 NA 
9 0 ± 0 1.5 ± 1.1 103.3 ± 3.1 1.03 
10 0 ± 0 0.1 ± 0.1 103 ± 0.9 1.03 
11 101.4 ± 3 106.6 ± 2.2 114.3 ± 0.1 1.14 
12 0 ± 0 0.1 ± 0.1 91 ± 6.1 0.91 
13 1 ± 0.3 1.2 ± 0.1 0.2 ± 0.3 NA 
14 3.6 ± 0.3 3.7 ± 0.1 4 ± 0.3 NA 
15 90.9 ± 1.8 93.8 ± 0.9 86.8 ± 1.3 NA 
16 52.4 ± 2.1 107.5 ± 2.9 99.5 ± 0.6 1.00 
17 56.8 ± 2.1 105.7 ± 6.2 88.8 ± 9.3 NA 
18 113.2 ± 10 102.6 ± 12.5 29.5 ± 6.6 0.30 
19 0 ± 0 0.9 ± 0.1 20.1 ± 9.4 NA 
20 19.3 ± 1.7 100.6 ± 2.6 109.1 ± 4.5 1.09 
21 113.2 ± 10 102.6 ± 12.5 29.5 ± 6.6 0.30 
22 0.5 ± 0 0.5 ± 0.2 109.2 ± 8.5 1.09 
23 64.6 ± 4.9 116.5 ± 6.1 NA NA 
24 0 ± 0 0 ± 0.1 1 ± 0.7 0.01 
25 0 ± 0 0 ± 0 82 ± 6.5 0.82 
26 0 ± 0 0 ± 0 94.4 ± 2.4 0.94 
27 1.1 ± 0.1 1.7 ± 0.2 114 ± 14.7 1.21 
28 0.3 ± 0.1 0.4 ± 0.1 4.3 ± 2.3 NA 
29 0 ± 0 0.2 ± 0.1 102.4 ± 1.9 1.02 
30 0 ± 0 0.1 ± 0 104.1 ± 0.4 1.04 
31 0 ± 0 0.3 ± 0.4 122.8 ± 7.9 1.23 
32 0.1 ± 0 0.1 ± 0.1 85.6 ± 0.1 0.86 
33 94.3 ± 4.7 100.6 ± 0.4 105 ± 2.9 1.06 
34 95.5 ± 1.3 101.1 ± 1.1 94.7 ± 2.8 0.95 
35 10.5 ± 1.7 13.1 ± 0.9 4.6 ± 2 NA 
36 0 ± 0 0.1 ± 0.1 89.7 ± 1.4 0.90 
37 78.8 ± 3.8 115.5 ± 9.9 107.5 ± 16.7 1.08 
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38 0 ± 0 0 ± 0 85.9 ± 2.7 0.86 
39 108.9 ± 3 112.5 ± 0.2 97.5 ± 4.1 0.97 
40 83.1 ± 15.2 82.6 ± 1.7 99.1 ± 13 0.99 
41 67.7 ± 1.3 95.7 ± 3.8 98.1 ± 0.9 1.03 
42 67.7 ± 1.6 75.4 ± 6.7 85.1 ± 3.6 0.85 
43 110.4 ± 10.6 129.9 ± 1.4 98.6 ± 19.1 0.99 
44 0 ± 0 1.5 ± 2.1 119.5 ± 11.8 1.20 
45 68.5 ± 0.3 61.1 ± 6.5 119.4 ± 11.4 NA 
46 61.7 ± 12.2 78.9 ± 0.3 94.4 ± 13.7 0.94 
47 18.6 ± 0.9 93.5 ± 1.6 90.4 ± 3 0.95 
48 5.6 ± 1.5 6.8 ± 0.8 20.6 ± 5.9 0.21 
49 95.7 ± 1.7 100.6 ± 1.5 102.8 ± 0.8 1.03 
50 0 ± 0 0.2 ± 0.2 105.1 ± 11.6 1.05 
51 60.3 ± 6.9 60.8 ± 4.8 99.9 ± 0.8 1.06 
52 97 ± 1.8 102.4 ± 3 100.8 ± 2.7 1.01 
53 106.7 ± 3.1 116 ± 8.9 NA NA 
54 34.7 ± 1.2 97.4 ± 1.9 125.9 ± 2.7 1.26 
55 0 ± 0 0 ± 0 82.1 ± 2.6 0.82 
56 0 ± 0 0 ± 0 0 ± 0 NA 
57 0 ± 0 0 ± 0 74.8 ± 5.4 0.75 
58 0 ± 0 0 ± 0 96.2 ± 6.9 0.96 
59 0 ± 0 0 ± 0 116.8 ± 11.7 1.17 
60 0 ± 0 1.7 ± 0.1 125.3 ± 14.2 1.25 
61 104.5 ± 1.4 108 ± 4.9 108.4 ± 1.8 1.08 
62 0.1 ± 0.1 0 ± 0 101.7 ± 5.8 1.02 
63 66.3 ± 6.5 91.6 ± 8.2 103.9 ± 8.5 1.04 
64 7.1 ± 1.4 21.7 ± 2.3 8.8 ± 7.3 NA 
65 23.5 ± 1.3 47.8 ± 3.2 86.8 ± 5.6 0.87 
66 122.9 ± 12.3 125.6 ± 6.6 91 ± 9.3 0.91 
67 39.5 ± 9.8 106.4 ± 14 NA NA 
68 78.9 ± 4.3 101 ± 1 94.9 ± 9.8 0.95 
69 10.5 ± 7.1 128.2 ± 15.8 26.9 ± 11.5 0.27 
70 0 ± 0 0.1 ± 0.1 95 ± 2.3 0.95 
71 95.3 ± 1.5 99.6 ± 4 112.8 ± 8.7 1.13 
72 0.1 ± 0.1 0 ± 0 95.4 ± 4.8 0.95 
73 64.4 ± 2.8 69.4 ± 2.5 NA NA 
74 68.5 ± 0.5 105.1 ± 1.9 83.8 ± 29.2 1.08 
75 89.7 ± 3.2 95.3 ± 1.8 112.7 ± 1.6 1.13 
76 100.8 ± 3.5 107.9 ± 3.5 106.1 ± 1 1.06 
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77 0.1 ± 0.1 0 ± 0 93.5 ± 1.4 0.94 
78 2.5 ± 0.3 117.5 ± 5 93.8 ± 5.6 0.94 
79 70.5 ± 12.6 76.9 ± 0.2 NA NA 
80 63.9 ± 1.4 67.2 ± 3.1 81.9 ± 7.6 0.82 
81 76.9 ± 5.8 76.2 ± 7.3 82.3 ± 12.5 0.82 
82 87.4 ± 2.2 95.9 ± 0.2 106.6 ± 3.6 NA 
83 0 ± 0 0.1 ± 0.1 84.3 ± 1.5 0.84 
84 0 ± 0 0 ± 0 62.6 ± 4.3 0.63 
85 0 ± 0 0 ± 0 103.5 ± 9.1 1.04 
86 83 ± 1.5 89 ± 1.2 84.9 ± 1.8 0.94 
87 0 ± 0 0 ± 0 87.5 ± 5.8 0.87 
88 0 ± 0 0 ± 0 7.7 ± 5.4 0.08 
89 72.2 ± 11.1 99.3 ± 6.2 116.1 ± 13.1 1.16 
90 1.8 ± 0.1 3.7 ± 0.3 39.9 ± 1.9 0.75 
91 124.2 ± 11.2 125.1 ± 3.7 108.8 ± 11.9 1.09 
92 1.1 ± 0 0.9 ± 0.2 2.9 ± 0.3 0.03 
93 1.8 ± 0 2.2 ± 0.1 2.2 ± 0.1 0.26 
94 32 ± 4.2 108.7 ± 1.6 106 ± 0 1.06 
95 48.3 ± 7.2 124.8 ± 4.1 111.4 ± 9.5 NA 
96 0 ± 0 0 ± 0 57.8 ± 1.9 0.58 
97 77.2 ± 2 91 ± 2 120.5 ± 9.7 1.21 
98 100.4 ± 19.8 108.3 ± 5.4 111.4 ± 3.1 1.11 
99 0.1 ± 0.1 95 ± 0 106.6 ± 0.3 1.07 
100 115.7 ± 15.1 106 ± 10.1 107.2 ± 8.3 NA 
101 3 ± 0.4 0 ± 0 0 ± 0 NA 
102 117.3 ± 4.8 113.4 ± 6.4 107.1 ± 12 1.07 
103 0 ± 0 120 ± 0 120.2 ± 14.8 1.20 
104 62.9 ± 26.5 78.8 ± 3.2 94.2 ± 14.6 1.09 
105 90.1 ± 5.6 102.8 ± 1.3 103.5 ± 0.5 1.04 
106 0 ± 0 0 ± 0 85.7 ± 2.6 0.86 
107 116.4 ± 3.5 124.5 ± 2.6 92.9 ± 2.1 0.93 
108 0 ± 0 0 ± 0 112.2 ± 2.6 1.12 
109 1.8 ± 0.2 1.6 ± 0.1 0 ± 0 NA 
110 0 ± 0 0 ± 0 101.9 ± 6.7 1.02 
111 10.9 ± 0.6 124.6 ± 2.6 76.4 ± 9.9 0.77 
112 124.7 ± 3.2 121.7 ± 3.2 91.5 ± 30.5 0.92 
113 0 ± 0 0 ± 0.1 103.7 ± 7.6 1.04 
114 96.2 ± 0.9 107.6 ± 9.8 111.7 ± 1.6 1.12 
115 101.4 ± 2.6 106.1 ± 4 104.7 ± 1.7 1.05 
  95 
116 41.4 ± 17.1 55.5 ± 0.2 65.8 ± 10.3 0.85 
117 90.4 ± 4.3 96.6 ± 0.7 112.3 ± 4.2 1.12 
118 0.2 ± 0.1 44.5 ± 2.3 79.6 ± 7.5 0.80 
119 18.9 ± 0.2 94.4 ± 6.5 93.2 ± 1.4 0.93 
120 0.4 ± 0.2 0.7 ± 0 0.5 ± 0.7 NA 
121 0 ± 0 0 ± 0 113.6 ± 18.9 1.14 
122 55.4 ± 22.6 81 ± 2 73.9 ± 4.4 0.74 
123 44 ± 3.4 49.5 ± 5.1 64.9 ± 1.4 NA 
124 60.4 ± 1.1 72.5 ± 4.1 86.1 ± 1 0.86 
125 0 ± 0 0 ± 0 0.4 ± 0.6 0.06 
126 0 ± 0 0 ± 0 108.6 ± 1 1.09 
127 97.7 ± 4.5 108.3 ± 6.1 113.9 ± 13.1 1.14 
128 0 ± 0 126.3 ± 4.9 99.8 ± 14.5 NA 
129 29.5 ± 0.6 49.1 ± 0.5 36.6 ± 11.4 0.37 
130 0 ± 0 0 ± 0 94.8 ± 0.5 NA 
131 0 ± 0 0 ± 0 96.8 ± 7.5 0.97 
132 43.7 ± 2.9 55.9 ± 0.7 82.5 ± 5.6 0.83 
133 0 ± 0 0.1 ± 0.2 93.9 ± 14 0.94 
134 10.8 ± 4.8 108 ± 6.7 78.9 ± 3.7 0.79 
135 0 ± 0 0 ± 0 0.4 ± 0.5 NA 
136 0 ± 0 0 ± 0 0 ± 0 NA 
137 0 ± 0 0 ± 0 0 ± 0 NA 
138 86.1 ± 5.3 102.2 ± 3.6 113 ± 4.2 1.13 
139 87.1 ± 2.5 98.1 ± 0 102.2 ± 10.1 1.02 
140 0 ± 0 69.3 ± 0.6 NA NA 
141 34.1 ± 0.8 64.4 ± 0.1 43.3 ± 5.4 0.59 
142 11.8 ± 0.4 38.8 ± 0.4 13.6 ± 3.4 NA 
143 0 ± 0 92.3 ± 1.8 92.8 ± 2.7 0.93 
144 99.5 ± 19.3 100.2 ± 0.4 87.9 ± 12.9 0.91 
145 67.2 ± 7 60.2 ± 2 120.6 ± 0.4 1.21 
146 100.1 ± 3.8 100.1 ± 1 108.6 ± 4 1.09 
147 0.7 ± 0.3 91.4 ± 3.3 102 ± 1 1.02 
148 56.5 ± 0.6 77.9 ± 7.7 86.4 ± 0 0.86 
149 50.1 ± 20.5 69.9 ± 1.4 89.1 ± 15.3 1.00 
150 13.2 ± 3.1 49.8 ± 4.8 NA NA 
151 28.9 ± 14.4 66.1 ± 2.2 72.8 ± 12.2 0.73 
152 0 ± 0 1.1 ± 0.6 121.5 ± 6.1 1.22 
153 80.5 ± 4.2 103.7 ± 3.6 90.8 ± 7.7 0.91 
154 0.3 ± 0 0.5 ± 0.1 0.4 ± 0.1 0.09 
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155 0.2 ± 0.3 0.9 ± 0.2 0.4 ± 0.2 0.12 
156 79.9 ± 0.2 81.7 ± 8.5 97 ± 13.6 0.97 
157 78.1 ± 0.5 94.5 ± 2.9 120.5 ± 1 1.21 
158 0 ± 0 0.5 ± 0.7 58.5 ± 27.1 0.59 
159 96.9 ± 4.5 114.4 ± 5.3 92.5 ± 6.7 0.92 
160 1.8 ± 0.2 1.4 ± 0 89.9 ± 8.8 0.94 
161 13.3 ± 0.2 102.1 ± 12.9 NA NA 
162 0 ± 0 0 ± 0 12.6 ± 2.8 NA 
163 3.5 ± 0.2 7.2 ± 0.3 77.7 ± 3.2 1.01 
164 0 ± 0 0 ± 0 37.6 ± 3.4 NA 
165 120.9 ± 6.1 101.4 ± 12.8 99.4 ± 16.1 0.99 
166 106.4 ± 0.4 104.7 ± 9.6 99.3 ± 2 0.99 
167 0 ± 0 0 ± 0 107 ± 17 1.07 
168 5.8 ± 1.8 6.2 ± 0.6 58.9 ± 6.5 5.18 
169 4 ± 2.7 4.6 ± 1.2 22.1 ± 8.6 0.22 
170 11.6 ± 7 5.8 ± 2.1 21.3 ± 4.4 0.21 
171 19.9 ± 7 10.2 ± 1.1 32.7 ± 6.2 0.33 
172 0.1 ± 0.1 1.9 ± 0.1 1.1 ± 1.5 NA 
173 74.5 ± 7.9 102.7 ± 0.3 NA NA 
174 47.9 ± 3.1 107.2 ± 3.4 112.9 ± 1.5 1.13 
175 113.2 ± 9 116.7 ± 15.1 102.8 ± 16.6 1.03 
176 113.3 ± 2.3 124 ± 5.9 100.8 ± 3.9 1.01 
177 29.2 ± 0.3 55.4 ± 2.1 65.4 ± 4.9 0.89 
178 0 ± 0 0.2 ± 0 98.5 ± 2.2 0.98 
179 0 ± 0 0.1 ± 0.1 95 ± 2.3 0.95 
180 0 ± 0 0.4 ± 0.6 128.2 ± 5.7 1.28 
181 6.4 ± 0.4 14.6 ± 2.9 50.5 ± 12.4 0.51 
182 79.7 ± 4.8 83.4 ± 2.3 0 ± 0 0.00 
183 0 ± 0 0.1 ± 0.1 92 ± 3.2 0.92 
184 8.3 ± 6.7 119.3 ± 0.4 17.5 ± 12.4 0.18 
185 84.9 ± 5.5 96.6 ± 1.8 99.6 ± 2.6 1.00 
186 107.6 ± 3.6 107.5 ± 2.5 68.6 ± 5.2 0.69 
187 0 ± 0 0 ± 0 100.9 ± 2.1 1.01 
188 0 ± 0 0 ± 0 51.2 ± 7.2 0.51 
189 6.8 ± 0.4 7 ± 0.1 55.4 ± 1.8 0.55 
a. No. refers to targeted compounds in Table B; 
b. Standard deviations were calculated from 3 replicates; 
c. NA means not available, 9 compounds cannot be detected or detected well using current instrumental methods; 
d. R/C ratio are the relative recovery rates calculated for compounds under optimized P-CDP SPE procedure (optimized 
capture and recovery condition). 
